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ABSTRACT
HOLLY GENTRY: Structural and Biochemical Characterization of CIB1
(Under the direction of Leslie V. Parise, Ph.D.)
CIB1 (CIB) is an EF-hand containing protein that binds the platelet IIb3 integrin
and several serine/threonine kinases to modulate their functions. The crystal structure for
Ca2+-bound CIB1 has been determined at 2.0 Å resolution and reveals a compact -helical
protein containing four EF-hands, the last two of which bind calcium ions. CIB1 shares high
structural similarity with calcineurin B (CnB) and the neuronal calcium sensor (NCS) family
of EF-hand containing proteins. Most importantly, like CnB and NCS proteins, which
possess a large hydrophobic pocket necessary for ligand binding, CIB1 contains a
hydrophobic pocket that has been implicated in ligand binding by previous mutational
analysis and NMR data. However, unlike several NCS proteins, Ca2+-bound CIB1 is largely
monomeric whether bound to a relevant peptide ligand or ligand-free. Differences in
structure, oligomeric state, and phylogeny define a new family of CIB1-related proteins that
extends from arthropods to humans.
In addition to binding IIb3, CIB1 binds additional  integrins, including 2, 4, 5,
L, and M with micromolar affinities. CIB1 inhibits agonist-induced activation of IIb3,
and future work will determine if CIB1 affects the activation states of these additional
binding partners.
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CHAPTER I − INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
1.1 Integrins 
 1.1.1 General characteristics 
 Integrins are heterodimeric transmembrane receptors that mediate cell-cell and cell-
substrate interactions by binding to extracellular matrix proteins.  Integrins consist of an α 
and β subunit that exist in a resting conformation on unactivated cells and convert to an 
active conformation upon cell stimulation, resulting in a conformational change that allows 
the integrin to bind its adhesive protein ligands with higher affinity.  Integrins are critical for 
adhesion and migration and their dysfunction is associated with many disease processes, 
including heart disease and cancer.  Signaling to integrins can occur by an “outside-in” 
mechanism, by which extracellular matrix proteins activate integrins by binding to their 
extracellular head domains.  This leads to a variety of signaling events inside the cell.  
Integrins can also be activated by an “inside-out” mechanism in response to agonist 
stimulation, which activates signaling pathways that lead to integrin activation and increased 
ligand binding. 
 1.1.2 Integrin structure overview 
 Integrins are comprised of two noncovalently attached α and β subunits.  Each has a 
large extracellular domain of over 600 residues in length, a single transmembrane domain, 
and a short cytoplasmic tail.  The structure of the extracellular portions of several integrins 
has been determined by x-ray crystallography.  The transmembrane region has been studied 
by mutational analysis and electron microscopy.  The structure of the short cytoplasmic tails 
of αIIbβ3 has been studied by NMR. 
 1.1.3 Extracellular domain 
 The first structure of the entire extracelluar domain of an integrin was that of αVβ3 
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(Xiong et al., 2001).  The structure of the large extracellular segment of αVβ3 has two bound 
“head” domains starting at the N-terminus (Fig. 1.1).  The αV subunit consists of a β-
propeller in this region, and the β3 subunit consists of a globular head with an 
immunoglobulin (Ig)-like “hybrid” domain (βI).  Two linked tail regions emerge from the 
head domains.  The αV tail is composed of three β sandwich domains, the first of which is an 
Ig-like “thigh” domain and two similar “calf” domains.  The β3 tail starts with a plexin, 
semaphorin and integrin (PSI) domain followed by four epidermal growth factor (EGF) 
domains and a β-tail domain (βTD).  There is a bend between the thigh and calf regions of 
αV, making both α and β head domains “bow” down toward the cell membrane.  This bent 
structure is likely to represent a low affinity conformation of the integrin (Takagi et al., 
2002).  However, the bent structure might be an artifact of crystallization because electron 
microscopy images of αIIbβ3 reveal an extended conformation (Litvinov et al., 2004).  
Additional studies of structures of the head domains of active αVβ3 (Xiong et al., 2002), 
αIIbβ3 (Xiao et al., 2004), and αLβ2 (Song et al., 2005) suggest an extended, unbent 
conformation when activated. 
 1.1.4 I and I-like domains 
 All integrin β subunits and half of integrin α subunits contain von Willebrand factor 
(vWF)-type A domains of approximately 200 residue (Shimaoka, Springer, 2003).  These 
domains are termed I domains in α subunits and I-like domains in β subunits.  These 
domains contain an α/β Rossman fold with a metal-ion-dependent adhesion site (MIDAS) at 
the top of the domain.  Coordination of a divalent cation at MIDAS is critical for ligand 
recognition and binding.  In integrins with an I domain, ligands bind directly to this domain 
and stabilize the high-affinity conformation (Shimaoka et al., 2003). 
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 The β subunit I-like domain has many of the same characteristics of the I domain, and 
in α integrins that lack the I domain, including αIIb, αV, and α5, the I-like domain is part of 
the ligand-binding surface (Shimaoka, Springer, 2003).  The I-like domain contains a 
MIDAS as well as a specificity-determining loop (SDL)(Takagi et al., 1997).  On either side 
of the MIDAS are two additional metal coordination sites, the adjacent to MIDAS site 
(ADMIDAS) and the ligand-associated metal binding site (LIMBS)(Xiong et al., 2002).  
Ligand binding to integrins lacking the α subunit I domain occurs on the α subunit β-
propeller domain and the β subunit I-like domain (Xiao et al., 2004;Xiong et al., 2002). 
 Like the I domain of α subunits, the I-like domain of β subunits has a C-terminal α-
helix (α7) that shifts to a high-affinity binding conformation upon ligand binding (Shimaoka 
et al., 2002).  In addition, the geometry of MIDAS is altered.  The crystal structure of the 
extracellular portion of αIIbβ3 with fibrinogen-mimetic therapeutics reveals how ligand 
binding is communicated to the rest of the integrin in integrins lacking an I domain.  The 
head domain of this ligand-bound integrin is in an “open” conformation and is critical for 
transmitting the activation signal to the rest of the integrin.  Compared to the closed structure 
of αVβ3, where the α and β tails are close to one another, αIIb is in an open conformation 
where the α7 helix of the β3 head domain is shifted, resulting in a 70 Å displacement of the 
PSI domain (Xiao et al., 2004) away from the α tail.  This open conformation is similar to 
electron microscopy (EM) images of αIIbβ3 in the presence of Mn2+, which is used 
experimentally to activate the integrin (Litvinov et al., 2004). 
 1.1.5 Transmembrane and cytoplasmic domain 
 Each α and β integrin subunit spans the membrane one time as an α-helix that 
associates with one another in the low-affinity state (Adair, Yeager, 2002;Partridge et al., 
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Fig. 1.1.  Structure of the αVβ3 ectodomain.  (A)  Ribbon diagram of the x-ray structure 
of unliganded αVβ3.  The integrin is bent at the "knee", called the α genu.  Ca2+ ions are 
indicated by purple sphere.  (B)  Model of αVβ3 in an extended inactive state.  Upon ligand 
binding, the α7 helix pushes against the hybrid domain, causing a 69 outward shift in the 
hybrid domain.  Reprinted, with permission, from the Annual Review of Cell and 
Developmental Biology, Volume 21 © 2005 by Annual Reviews www.annualreviews.org.
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2005).  Upon agonist stimulation, the transmembrane helices separate (Luo et al., 2004).  In 
addition, agonist stimulation causes a membrane-proximal portion of the intracellular tails to 
become buried in the membrane (Armulik et al., 1999;Stefansson et al., 2004;Vinogradova et 
al., 2004).  Using transferred nuclear Overhauser effect (NOE) experiments, deuterated 
dodecylphosphocholine (DPC) detergent micelles added to αIIb or β3 induced significant 
spectral perturbation changes when compared to αIIb or β3 in the absence of DPC 
(Vinogradova et al., 2004). 
 The short cytoplasmic tails of α and β integrin subunits interact as α-helices close to 
the membrane (Fig 1.2)(Vinogradova et al., 2002).  This interaction constrains integrins in a 
low-affinity state.  Several pieces of data, including the EM images described above 
(Litvinov et al., 2004), point to the α and β cytoplasmic tails separating upon activation.  
Deletion of the cytoplasmic tail of either αIIb or β3 activates the integrin (Ma et al., 
2006;O'Toole et al., 1994).  Fluorescence resonance energy transfer (FRET) analysis of αLβ2 
suggests separation of α and β cytoplasmic tails during inside-out and outside-in signaling 
(Kim et al., 2003).  In addition, point mutations that disrupt the interaction between α and β 
cytoplasmic tails induce constitutive activation (Hughes et al., 1995;Lu, Springer, 1997).  
Talin, a protein that binds β integrin subunits and activates integrins, leads to α and β tail 
separation upon binding to β3 (Kim et al., 2003;Vinogradova et al., 2002). 
 1.1.6 Integrin function and therapeutics 
 Eighteen α subunits and eight β subunits combine to form 24 different heterodimers.  
Integrins interact with a wide variety of ligands, including soluble and surface-bound 
proteins.  Some integrins, such as α5β1, are specific for one particular ligand.  Some integrin 
subunits, such as αV, interact with many β subunits and have a variety of different ligands. 
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Fig. 1.2.  Model of talin-induced integrin activation.  Agonist stimulation induces 
exposure of the talin head domain (H).  The talin head domain binds the β3 tail at the NPLY 
motif and the membrane-proximal helix.  Binding the membrane-proximal helix disrupts 
the interaction between αIIb and β3, and binding the NPLY motif releases the membrane 
anchor and allows further unclasping of the integrin.  Green rectangles highlight regions of 
αIIb and β3 that shift into the membrane upon integrin activation.  Adapted from Qin et al., 
2004.
αIIb β3
Talin
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 αIIbβ3
 The αIIbβ3 integrin is specific to platetets and their precursor cells, megakaryocytes.  
It is the most abundant integrin on platelets with 80,000 copies on each unstimulated platelet.  
The αIIb and β3 subunits assemble in the endoplasmic reticulum (Duperray et al., 1987). 
 The αIIbβ3 integrin is essential in hemostasis and thrombosis.  Thrombi in arterial 
circulation occur as a result of αIIbβ3-mediated platelet aggregation (Lefkovits et al., 1995).  
The inherited disease Glanzmann thrombasthenia results from mutations in αIIbβ3 (George et 
al., 1990). 
 In the United States, nearly one million people die every year from cardiovascular 
disease (CVD)(Statistics at www.americanheart.org).  Critical to CVD is thrombus 
formation, which involves platelet aggregation mediated by fibrinogen crosslinking via αIIbβ3 
(Bhatt, Topol, 2000).  The αIIbβ3 integrin is unique in that it is specific to platelets, so 
therapeutics that target it do not adversely affect other cell types.  The first αIIbβ3 antagonist 
to be developed was abciximab (ReoPro™), a Fab fragment of a monoclonal antibody that 
recognizes activated αIIbβ3.  It is used as an adjunt therapy for percutaneous coronary 
intervention (PCI)(Bhatt, Topol, 2000).  Two small molecule αIIbβ3 inhibitors are based on 
the RGD sequence, eptifibatide (Integrilin™)(O'Shea et al., 2001) and tirofiban 
(Aggrestat™)(Topol et al., 2001).  They are given intravenously and are used to treat acute 
coronary syndrome. 
 The downside of these therapeutics is that although they prevent platelets from 
adhering to one another, they are not orally available and have the potential to act as partial 
agonists (Cox et al., 2000;Du et al., 1991), resulting in platelet release of vasoactive 
compounds such as ADP, serotonin, and thromboxane A2 (TxA2).  A different strategy for 
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designing therapeutics could involve the cytoplasmic domains of αIIbβ3 rather than the ligand 
binding extracellular domains.  The importance of the cytoplasmic tails in αIIbβ3 activation 
has been highlighted in studies using mutants in which one of the tails of the subunit has 
been deleted.  Deletion of either of the cytoplasmic tails of αIIbβ3 results in integrin activation 
(O'Toole et al., 1994).  In addition, a cell-permeable peptide corresponding to the highly-
conserved membrane proximal portion of αIIb (989KVGFFKR) enhances αIIbβ3 activation 
and aggregation and leads to generation of thromboxane A2 (TxA2)(Stephens et al., 1998).  
Isolated β tails can signal downstream to focal adhesion kinase (FAK)(Tahiliani et al., 1997).  
In Chapter III, we will explore the interaction of a cytosolic protein with α integrin 
cytoplasmic tails.  Knowledge of the dynamics of integrin cytoplasmic tails will hopefully 
increase our potential targets for therapeutic development. 
 α2β1
 The α2β1 integrin is found on melanoma cells, platelets, and fibroblasts (Cox et al., 
1994) and binds a variety of ligands such as collagen, laminin, and thrombospondin.  Initial 
adhesion of melanoma cells to collagen is dependent on α2β1 (Montgomery et al., 1994).  
Activation of platelets in thrombotic events is partially mediated by platelet α2β1 binding to 
collagen in blood vessel walls (Beutler E, 2001). 
 α4β1 and α4β7
 The α4 integrins, α4β1 (VLA-1) and α4β7, are important in leukocyte physiology, 
blood cell maturation, embryogenesis, and lymphocyte homing (Springer, 1994).  The α4β1 
integrin is the only integrin on immature sickle red blood cells in sickle cell disease (Joneckis 
et al., 1993) and binds to thrombospondin, which is elevated in the plasma of patients with 
this disease (Brittain et al., 2004).  In autoimmune diseases, leukocyte accumulation in 
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affected tissues corresponds to pathogenesis (Hynes, 1992).  Increased expression of cellular 
adhesion molecules (CAMs), including the primary ligand of α4β1, vascular cell adhesion 
molecule (VCAM)(Elices et al., 1990), and the primary ligand of α4β7, mucosal addressin 
cell adhesion molecule (MAdCAM)(Berlin et al., 1993), is associated with autoimmune 
diseases.  These ligands are expressed on the surface of vascular endothelial cells and 
mediate leukocyte invasion into affected tissues via a α4β1/VCAM or α4β7/MAdCAM 
interaction. 
 Monoclonal antibodies against these integrins or their CAM ligands decreases 
inflammation in animal models (Kummer, Ginsberg, 2006).  In addition, an α4 antibody-
based antagonist, natalizumab, decreases inflammation in patients with Crohn’s disease and 
relapsing multiple sclerosis, although it has caused progressive multinodal 
leukoencephalopathy (PML) in three patients (Engelhardt, Briskin, 2005).  Further study will 
hopefully yield better therapeutics, including small molecule antagonists. 
 α5β1
 The α5β1 integrin is a fibronectin receptor that is found on many cell types, including 
epithelial cells and lymphocytes (Cox et al., 1994).  It is expressed on activated epithelial 
cells and participates in tumor angiogenesis.  A small peptide α5β1 antagonist used with the 
chemotherapeutic 5-fluorouracil (5-FU) decreases liver metastases in mice (Stoeltzing et al., 
2003) 
 αLβ2
 Leukocyte function-associated protein-1 (LFA-1), or αLβ2, is a leukocyte integrin that 
binds intracellular adhesion molecule-1 (ICAM-1), comprised of five tandem Ig-like 
domains, on the surface of antigen-presenting cells (APC) or vascular endothelial cells 
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(Anderson, Siahaan, 2003;Fortin et al., 1998).  LFA-1 is very important in lymphocytes, 
where the LFA-1/ICAM-1 interaction is necessary for T-cell activation as well as migration 
of T-cells to target tissues.  Therefore, blocking this interaction can suppress T-cell activation 
in autoimmune diseases and organ transplantation.  An antibody-based therapeutic, 
efalizumab, binds LFA-1 and is being used to treat the autoimmune disease psoriasis (Cather, 
Menter, 2005).  Small-molecule inhibitors of the LFA-1/ICAM-1 interaction are also being 
developed (Giblin, Lemieux, 2006).  In addition, structure-based design of therapeutics 
involves stabilizing αL in a low-affinity state.  The 3-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA) reductase inhibitor lovastatin, used to reduce plasma cholesterol levels, has 
been found to bind to LFA-1 and prevent binding to ICAM-1 (Weitz-Schmidt et al., 2001).  
Lovastatin reduces inflammation and derivatives specific for LFA-1 might be useful in 
treatment of diseases such as arthritis and psoriasis. 
 αMβ2
 Macrophage antigen-1 (Mac-1, αMβ2), is mainly expressed on neutrophils and binds 
ICAM-1, fibrinogen, and many other protein ligands (Shimaoka, Springer, 2004).  Targeting 
αMβ2 could be useful in diseases in which neutrophils are important, such as cerebral and 
myocardial infarction and shock. 
 αV
 The αV integrin subunit heterodimerizes with β1, β3, β5, β6, and β8.  The αVβ3 integrin 
is upregulated in many pathological conditions, such as metastatic melanoma, breast and 
prostate tumors, late stage glioblastoma, angiogenic vessels, atherosclerotic lesions, and 
inflamed tissues of patients with rheumatoid arthritis (Nadrah, Dolenc, 2005).  This integrin 
is abundant on osteoclasts as well as many other cell types.  An αVβ3 peptidomimetic therapy 
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based on the RGD sequence, Cilengitide, is in clinical trials as a cancer treatment 
(Dechantsreiter et al., 1999).  A number of small molecule RGD mimetics are also being 
studied with specificity for either αV or αIIbβ3 (Meyer et al., 2006). 
 1.1.7 Integrin intracellular signaling 
 Several proteins have been found to bind α and β cytoplasmic tails, and none have 
been as well-studied as the actin-binding protein talin.  Talin is a dumbbell-shaped 
homodimer (Goldmann et al., 1994) with a large C-terminal rod domain and an N-terminal 
head domain.  The head domain directly binds β (Calderwood et al., 1999) as well as α 
cytoplasmic tails (Knezevic et al., 1996).  Its binding to β tails causes α and β tail separation 
(Kim et al., 2003;Vinogradova et al., 2002) and activation (Calderwood, 2004;Kim et al., 
2003;Tadokoro et al., 2003;Vinogradova et al., 2002).  A recent NMR structure of talin and 
β3 peptide reveals contacts between talin and the membrane-proximal region of β3 (Wegener 
et al., 2007).  Binding of talin to this region of β3 likely disrupts interactions of α integrin 
subunits with β subunits. 
 Additional actin-binding proteins that bind integrin β subunits are α-actinin and 
filamin, which link integrins and the actin cytoskeleton at focal adhesions and stress fibers 
(Liu et al., 2000).  Focal adhesion kinase (FAK), a protein tyrosine kinase (PTK), colocalizes 
with integrins at focal adhesions and might bind β tails directly (Schlaepfer, Hunter, 1998).  
Its kinase activity is stimulated by integrin attachment to extracellular matrix proteins.  
Likewise, activity of p21-activated kinase (PAK1), a serine-threonine kinase, is stimulated by 
adhesion to extracellular matrix proteins.  Other PTKs that are involved in integrin signalling 
are proline-rich tyrosine kinase (Pyk2), Syk, and Src-family PTKs (Schlaepfer, Hunter, 
1998).  Adaptor proteins such as p130Cas and Grb2 link PTKs to the mitogen-activated 
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protein (MAP) kinase pathway, leading to JNK and ERK activation. 
1.2 EF-hand-containing proteins 
 1.2.1 General characteristics 
   An EF-hand is a Ca2+-binding helix-loop-helix motif that usually exists as part of a 
pair (Ikura, 1996).  This pair forms a domain that is often found with another pair of EF-
hands.  These two domains, or lobes, can function independently, as in the case of 
calmodulin, which has a flexible linker between its two lobes.  This flexibility lends to a 
variety of different binding surfaces available for calmodulin to bind substrates (Hoeflich, 
Ikura, 2002).  These two domains can also be rigidly set in a fixed orientation relative to one 
another, as in the case of recoverin (Ames et al., 1997;Ames et al., 2006) and calcineurin B 
(Griffith et al., 1995;Huai et al., 2002;Kissinger et al., 1995).  There are many small proteins 
with four EF-hands, and some have an odd number of EF-hands, such as the penta-EF-hand-
containing protein calpain, whose fifth EF-hand pairs with the fifth EF-hand of its dimer 
conjugate (Maki et al., 2002). 
 The loop portion of an EF-hand contains a consensus twelve amino acid sequence 
that is required for binding Ca2+.  Calcium ions bind canonical EF-hand loops with high 
affinity due to acidic residues at positions 1, 3, 5 and 12, where residues at positions 1, 3 and 
5 contribute individual ligands to the coordination sphere and the residue at position 12 
contributes two ligands (Michiels et al., 2002).  In most EF-hands, a backbone carbonyl at 
position 7 as well as a water molecule that is hydrogen-bonded to a sidechain oxygen from 
position 7 complete the coordination sphere, yielding a pentagonal bipyramidal geometry.  
Some EF-hands are unable to bind Ca2+ because they lack one or several Ca2+-binding 
residues. 
13
 EF-hand-containing proteins can be categorized into two groups depending on the 
Ca2+ affinity and function of their EF-hands (Ikura, 1996).  Some EF-hand-containing 
proteins, termed Ca2+ buffers, bind Ca2+ with very high affinity (~10-9).  Calcium is 
constitutively bound to these EF-hands, which are termed “structural” EF-hands because 
binding of Ca2+ simply stabilizes the structure of the protein (Ikura, 1996).  Other EF-hand-
containing proteins, including the ones discussed in detail in this work, contain “regulatory” 
EF-hands that undergo significant conformational changes upon Ca2+ binding.  These Ca2+ 
“sensors” bind Ca2+ at concentrations above the resting free Ca2+ concentration.  In this work, 
we will further discuss Ca2+ sensors that contain four EF-hands. 
 1.2.2 CIB1 
 CIB1 (CIB, calmyrin, KIP) is a 22 kDa EF-hand-containing protein that was 
originally identified as a binding partner for the αIIb integrin subunit in a yeast two-hybrid 
screen (Naik et al., 1997).  CIB1 contains four EF-hand domains (Fig 1.3)(denoted EF1-4), 
two of which (EF-3 and EF-4) bind Ca2+ at micromolar affinities (Yamniuk et al., 2004).  
CIB1 binding to αIIb appears to modulate the activation state of the integrin (Tsuboi, 
2002;Yuan et al., 2006b), platelet spreading (Naik, Naik, 2003b), and focal adhesion kinase 
(FAK) activation (Naik, Naik, 2003a).  CIB1 is N-terminally myristoylated (Stabler et al., 
1999) and is homologous to calmodulin, calcineurin B, and the neuronal calcium sensor 
family of proteins. 
 1.2.3 Calmodulin 
 CIB1 shares 27% identity with calmodulin (CaM), a highly conserved protein with a 
large number of targets including calmodulin-dependent protein kinases (CaMKs), myosin 
light chain kinases (MLCKs), and the Ca2+-activated K+ channel.  CaM has a highly flexible 
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Myr	 	 	 	 	 	 Ca2+                           Ca2+
Fig. 1.3.  Secondary structure of CIB1.  EF-hands are shown as green boxes, with EF3 
and EF4 binding Ca2+.  The consensus myristoylation site is shown as a pink box.
EF1                     EF2                        EF3                        EF4
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linker between its N and C lobes, allowing it bind substrates in a variety of different ways 
(Hoeflich, Ikura, 2002).  CaM activates CaMK II, the MLCKs, and CaM kinase kinase by 
interacting with the kinase autoinhibitory domain (AID), a pseudosubstrate that blocks the 
active site of the kinase.  In these interactions, CaM acts as a clamp by surrounding an α-
helix that is adjacent to or within the AID of the target.  In contrast to the compact 
conformation of CaM with these kinases, an extended CaM molecule binds to Bacillus 
anthracis adenylyl cyclase (Drum et al., 2002) with binding surfaces on either side of CaM.  
Rather than displacing an AID on the adenylyl cyclase, CaM binding induces a variety of 
confomational changes in critical switch regions that results in a stable substrate binding 
pocket. 
 1.2.4 Calcineurin B 
 CIB1 is also highly identical (27%) to calcineurin B (CnB), the regulatory molecule 
of the calcineurin (Cn) phosphatase, also known as protein phosphatase 2B.  Calcineurin is 
the target of the immunosuppressant drugs cyclosporin A and FK506 (Tacrolimus) in 
conjunction with their respective immunophilins, cyclophilin B and FKBP12 (Liu et al., 
1991).  These drugs inhibit T lymphocyte signal transduction and IL-2 transcription and are 
used to prevent rejection after organ transplantation. 
 The catalytic subunit of calcineurin, calcineurin A (CnA), requires both CnB and 
CaM for activation and drug binding (Aramburu et al., 2004).  CaM displaces the AID from 
CnA, and CnB binds an amphipathic α-helix that binds drug on its opposite side (Ke, Huai, 
2003).  Calcineurin is abundant in the nervous system, although it is found ubiquitously.  It 
has a relatively narrow substrate specificity, with one of its targets being the nuclear factor of 
activated T cell (NFAT) proteins (Crabtree, 2001).  The NFAT proteins form a transcription 
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complex that is important in a variety of functions, including T cell activation and embryonic 
cardiac valve formation.  Dephosphorylation of NFATs by calcineurin exposes nuclear 
localization sequences. 
 1.2.5 Neuronal calcium sensor proteins 
 CIB1 is also shares identity (~23%) to the neuronal calcium sensor (NCS) proteins.  
These proteins are termed neuronal calcium sensors (NCS) due to their neuronal expression 
pattern and high degree of homology (Braunewell, Gundelfinger, 1999).  These proteins have 
a variety of functions; recoverin directly inhibits rhodopsin kinase (Senin et al., 2002), while 
a subgroup of NCS proteins that includes frequenin modulates synaptic activity, 
neurotransmitter release, and vesicle secretion (Braunewell, Gundelfinger, 1999). 
  1.2.5.1  Ca2+-myristoyl switches 
 Certain NCS proteins are termed Ca2+-myristoyl-switch proteins.  Upon Ca2+ binding, 
Ca2+-myristoyl switch proteins undergo structural changes that allow them to bind and 
activate target proteins.  At least two specific structural changes can occur in these proteins 
due to Ca2+ binding that facilitate signal transduction.  The first type of change occurs when a 
hydrophobic binding pocket becomes accessible, thus facilitating ligand binding.  The second 
type of change, termed a myristoyl switch, involves the extrusion of an N-terminal myristoyl 
group from a hydrophobic cavity in the protein, thereby leading to membrane localization, as 
described in recoverin (Ames et al., 1997) and related proteins.  Surprisingly, some NCS 
proteins, such as frequenin, do not contain a Ca2+-myristoyl switch.  The myristoyl moiety of 
frequenin is constitutively solvent-exposed and not sequestered within the protein (Ames et 
al., 2000), and the cellular localization of frequenin is not changed in high or low 
concentrations of Ca2+ (O'Callaghan et al., 2002). 
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  1.2.5.2  Oligomerization 
 Another regulatory mechanism of NCS proteins is the ability to form dimers or 
tetramers under various conditions.  Many NCS homologs of CIB1 form dimers or tetramers 
under various conditions, including protein concentration, Ca2+ concentration, or the 
presence or absence of ligand.  For instance, KChIP3 tends to form tetramers at protein 
concentrations higher than 20 µM and stable dimers at low protein concentrations (Osawa et 
al., 2001).  Similarly, neurocalcin forms a dimer in the crystal (Vijay-Kumar, Kumar, 1999) 
and in solution when Ca2+ is present (Olshevskaya et al., 1999), but forms a monomer when 
Ca2+ is absent (Olshevskaya et al., 1999).  Conversely, GCAP-2 forms dimers in the absence 
of Ca2+ and monomers in the presence of Ca2+ (Olshevskaya et al., 1999).  Also, 
unmyristoylated recoverin forms a dimer within the asymmetric unit of the crystal structure 
(Flaherty et al., 1993), while KChIP1 also forms dimers, but only in the presence of ligand 
(Zhou et al., 2004). 
 1.2.6  Relationship of CIB1 to CaM, CnB, and NCS proteins 
 A comparison of CaM, CnB, NCS proteins, and CIB1 is shown in Table 1.1.  All are 
small homologous proteins with four EF-hands.  It is our goal to determine the relationship of 
CIB1 to its homologs.  Based on the characteristics that are known, it is possible to draw 
some conclusions about the likely position of CIB1 within this group. 
 CIB1 and its homologs are considered Ca2+ sensors rather than buffers, since they 
bind Ca2+ at concentrations above basal (Burgoyne, Weiss, 2001).  Calcium binding is not 
required for many of the activities of CIB1 and its homologs, although it appears to enhance 
these activities.  CIB1 can bind αIIb in the absence of divalent cations, and binds αIIb with 
equally high affinity in resting Mg2+ concentrations as it does in the presence of Ca2+ 
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CaM
4
4
10-5
no
no
no
yes
varied
ubiquitous
54%
# EF-hands
Ca2+ affinity (M)
Myristoylation
Ca2+-myristoyl switch
Dimerization
Flexible linker
Ligand binding site
Expression
Homology to CIB1
CnB
4
4
10-6
yes
no
no
no
ubiquitous
57%
NCS
4
2-3
10-7
yes; most
yes; some
yes; some
no
neuronal
~45%
CIB1
4
2
10-6
yes
no
?
no
?
ubiquitous
-
Table 1.1.  Comparison of calmodulin (CaM), calcineurin B (CnB), neuronal calcium 
sensors (NCS), and CIB1.  
# Ca2+-binding EF-
hands
hydrophobic
pocket
hydrophobic
pocket
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(Yamniuk, Vogel, 2005).  The structure of CIB1 in the presence of Ca2+ or Mg2+ is expected 
to be very similar, since the number of detected peaks and spectral dispersion by 
heteronuclear single quantum correlation (HSQC), a kind of nuclear magnetic resonance 
(NMR) spectroscopy, is very similar for each.  However, fewer well-resolved peaks are 
detected for Mg2+-bound CIB1, suggesting Mg2+-CIB1 is more flexible than Ca2+-CIB1.  
These data are in agreement with circular dichroism (CD) and differential scanning 
calorimetry (DSC) studies.  Binding to Ca2+ therefore stabilizes the structure of CIB1 and 
might increase its ability to bind ligand efficiently in vivo.  Other homologs of CIB1 can also 
interact with ligands in the absence of Ca2+.  While Ca2+ binding is required for efficient 
activation of CaM, it binds some targets, including anthrax adenylyl cyclase (Leppla, 1984) 
and the ryanodine receptor (Samso, Wagenknecht, 2002), in its apo form.  Binding of Ca2+ to 
CnB is not required for binding to its catalytic subunit, CnA (Stemmer, Klee, 1994), although 
binding of Ca2+ to EF-2 is important for efficient activation of calcineurin A.  The activity of 
NCS proteins is also enhanced by Ca2+.  In the case of recoverin, the presence of the 
myristoyl group makes the presence of Ca2+ more critical for binding rhodopsin kinase, since 
unmyristoylated, but not myristoylated, recoverin binds rhodopsin kinase in the presence of 
EGTA (Ames et al., 2006).  Based on these data from CIB1 and its homologs, it is likely that 
their effectiveness in binding ligand is fine-tuned by Ca2+ binding. 
 CaM is unique among CIB1 homologs in several ways.  First, its affinity for Ca2+ is 
10-fold lower than CnB, NCS proteins, and CIB1.  NCS proteins bind Ca2+ at levels just 
above basal Ca2+ concentrations and reach half maximal binding below 1 µM free Ca2+ 
(Burgoyne, Weiss, 2001).  Therefore, these proteins are fully active at intracellular Ca2+ 
concentrations that activate only a small fraction of calmodulin.  Two of the EF-hands of 
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CIB1, EF3 and EF4, bind Ca2+ sequentially with affinities of 1.9 and 0.54 µM, respectively 
(Yamniuk et al., 2004).  These values are comparable to the Ca2+ affinities seen in NCS 
proteins as well as calcineurin B. 
 Myristoylation is an important mechanism by which many homologs of CIB1 localize 
to membranes, and many NCS proteins are Ca2+-myristoyl switches (see section 1.2.5.1).  
CaM is unique is that it is not myristoylated or localized to cellular membranes.  CnB does 
not contain a Ca2+-myristoyl switch, and myristoylation is not required for its biological 
function (Kennedy et al., 1996a;Zhu et al., 1995), although it does contribute to thermal 
stability (Kennedy et al., 1996b).  CIB1 also does not appear to contain a Ca2+-myristoyl 
switch.  Upon treatment of Cos-7 cells with ionomycin, a Ca2+ ionophore that increases 
intracellular Ca2+ concentrations, CIB1 does not show a translocation to the membrane 
(Blazejczyk et al., 2006). 
 Binding of ligands to CaM is unique in that CaM has many different binding sites and 
assumes different conformations upon binding different ligands (Drum et al., 2002).  It 
contains a hydrophobic binding pocket in the same location as CnB and NCS proteins, but it 
can also bind ligand on the opposite side of the molecule from this pocket (Drum et al., 
2002).  CaM has a variety of binding mechanisms because of a flexible linker between its 
two lobes.  This linker allows CaM to adopt many different conformations, unlike the fixed 
orientation between lobes seen in CnB and NCS proteins.  It is thought that CIB1 is more 
similar structurally to CnB and the NCS proteins.  When homology modelling was performed 
with CIB1, CaM did not provide a good fit with CIB1, and CIB1 was modelled instead on 
the structures of CnB and recoverin (Barry et al., 2002).  In this model, CIB1 has a 
hydrophobic binding pocket in the same location as in CnB and the NCS proteins.  In 
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addition, mutations to residues in this region decreased binding to αIIb. 
 Based on characteristics discussed in this section, it is clear that CIB1 has more in 
common with CnB and NCS proteins than with CaM.  CIB1 is likely to bind ligand in a 
hydrophobic binding pocket similar to CnB and NCS proteins.  CIB1 is less identical in 
sequence to several NCS proteins, such as KChIP1 (24%), neurocalcin (23%), and frequenin 
(24%) than they are to one another (Braunewell, Gundelfinger, 1999).  In fact, CIB1 is more 
identical to CnB (27% identity) and is widely expressed (Shock et al., 1999), while NCS 
proteins are exclusively found in the nervous system and retina.  However, CIB1 might use 
oligomerization as a regulatory mechanism like the NCS proteins.  In Chapter 2, we will 
discuss the structural and biochemical analysis that helped determine the placement of CIB1 
within the realm of small EF-hand-containing proteins. 
1.3 CIB1 and its binding partners 
 1.3.1 αIIb
Since its discovery for binding αIIb, CIB1 has been implicated in αIIbβ3-mediated 
inside-out and outside-in activation.  CIB1 has also been implicated in αIIbβ3-mediated 
outside-in signaling upon platelet adhesion to fibrinogen (Naik, Naik, 2003b).  CIB1 co-
immunoprecipitates and colocalizes in Chinese hamster ovary (CHO) cells with focal 
adhesion kinase (FAK), a key regulator in focal adhesion formation.  However, a direct 
interaction between CIB1 and FAK was not shown (Naik, Naik, 2003a).  CIB1 has been 
found to inhibit agonist-induced αIIbβ3 activation (Yuan et al., 2006b).  Upon stimulation 
with protease activated receptor 4 (PAR4), a platelet agonist for the thrombin receptor, 
platelet precursor cells (megakaryocytes) exhibit decreased binding to fibrinogen, which is a 
readout for platelet activation.  In a complementary experiment, megakaryocytes treated with 
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CIB1 siRNA exhibit increased binding to fibrinogen.  
 CIB1 binds αIIb with higher affinity in the presence of Ca2+ (Yamniuk, Vogel, 2005), 
and Ca2+ levels increase upon platelet activation (Offermanns, 2006).  Since increased Ca2+ 
levels are associated with platelet activation and increased binding of CIB1 to αIIbβ3, 
increased CIB1 expression would be expected to lead to increased αIIbβ3 activation.  
However, our data suggest that overexpressed CIB1 inhibits agonist-induced platelet 
activation (Yuan et al., 2006b).  Since αIIbβ3 is far more abundant in platelets than CIB1, it 
appears that CIB1 holds a subpopulation of αIIbβ3 in an inactive state upon agonist 
stimulation.  
 The inhibition of αIIbβ3 by CIB1 is in contrast to the activating effect of the 
cytoskeletal protein talin on several integrins.  When talin is knocked down in Chinese 
hamster ovary (CHO) cells, there is decreased activation of several integrins, including 
αIIbβ3, when these integrins are overexpressed (Tadokoro et al., 2003), and additional studies 
also indicate that talin is required for the activation of certain integrins (Calderwood, 2004).  
Purified GST-CIB1 did increase fibrinogen binding of αIIbβ3 in vitro (Tsuboi, 2002).  We 
were able to reproduce this result, although CIB1 lacking a GST tag did not increase 
fibrinogen binding (unpublished data).  A palmitoylated peptide corresponding to the C-
terminus of CIB1 increased agonist-induced αIIbβ3 activation in washed platelets (Tsuboi, 
2002).  However, binding studies showed that a CIB1 mutant lacking the C-terminus binds 
αIIb with the same affinity as WT CIB1 (Yamniuk et al., 2006), so the C-terminus is not 
critical for αIIb binding.  Therefore, it appears that the C-terminal peptide was having a non-
specific effect on αIIbβ3 activity. 
 Direct, high-affinity (0.7 µM) binding of CIB1 to αIIb has been verified by isothermal 
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titration calorimetry (ITC)(Shock et al., 1999;Yamniuk, Vogel, 2005).  The CIB1 binding 
region of αIIb has been delineated and corresponds to a membrane-proximal portion of the 
cytoplasmic tail, including several amino acids within the putative transmembrane domain 
(Fig. 1.4)(Barry et al., 2002).  These binding residues of αIIb are likely to form an 
amphipathic α-helix (Adair, Yeager, 2002), which agrees with data showing that the 
hydrophobic crevices of EF-hand containing proteins bind α-helical regions, such as the 
binding of CnB to CnA (Griffith et al., 1995) and the binding of KChIP1 to the Kv4.2 
channel (Zhou et al., 2004).  Additional evidence for a hydrophobic interaction is that the 
residues of aIIb critical for binding to CIB1 are the nonpolar L983, W988, F992, and F993 
residues (Barry et al., 2002).  When any of these residues was mutated to an alanine, a loss of 
binding was seen by intrinsic tryptophan fluorescence (ITF).  In addition, an αIIb peptide 
lacking the residues 983LVL did not bind CIB1 by ITC (Shock et al., 1999).  Residue W988 
was also confirmed to be part of the binding interface by NMR studies (Yamniuk, Vogel, 
2005). 
 The mechanism of CIB1 inhibition of αIIbβ3 activation is unclear.  Talin seems to 
activate integrins by inducing integrin tail separation.  Adding talin to 15N-labeled β3 in the 
presence of αIIb caused different nuclear overhauser effects (NOEs) than β3 and αIIb alone, 
suggesting talin disrupts this interaction (Vinogradova et al., 2002).  Additional FRET data 
supports the idea that talin causes integrin tail separation (Kim et al., 2003).  Addition of 
CIB1 to 15N-labeled αIIb in the presence of β3 exhibits the same NOEs as αIIb and β3 tails 
alone, suggesting CIB1 does not disrupt the α/β interaction (Jun Qin, unpublished data).  
Additional study of the mechanism of action of CIB1 on αIIb is needed to clarify its role in 
αIIbβ3 inhibition. 
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 Additional integrin cytoplasmic domains (αV, α2, α5, β1, and β3) did not bind CIB1 
by yeast two-hybrid analysis (Naik et al., 1997).  At the time of these experiments, 
information about the CIB1 binding site on αIIb was unknown.  The sequences (outlined with 
black boxes, Fig 1.5) used for the experiments were lacking the hydrophobic region in the 
transmembrane domain that is critical for binding CIB1.  Recently, binding of CIB1 to α5 has 
been seen HSQC (Jun Qin, unpublished data).  In addition, overexpressed CIB1 inhibits 
α5β1-mediated migration of rat embryo fibroblast (REF52) and HeLa cells on fibronectin 
(Leisner et al., 2005).  In addition, CIB1 null endothelial cells have decreased α5-mediated 
migration (Mohamed Zayed, manuscript in submission).  This implicates CIB1 in the α5β1 
signalling pathway. 
 1.3.2 PAK1 
Since its discovery for binding αIIb, additional CIB1-binding proteins have been 
identified, including p21-activated kinase 1 (PAK1)(Leisner et al., 2005).  PAK1 is a serine-
threonine kinase involved with cellular motility.  It is activated by Cdc42 and Rac1, which 
disrupt PAK1 homodimerization and autoinhibition (Parrini et al., 2002).  There are also 
GTPase-independent mechanisms by which PAK is activated (Bokoch, 2003).  CIB1 
activates PAK1 independently of small GTPases in vitro and in vivo (Leisner et al., 2005).  
Two areas of PAK1 that bind CIB1 were identified by the SPOT peptide method.  These two 
peptides flank the GTPase-binding domain of PAK1, and CIB1 competes with Cdc42 for 
binding to PAK1.  CIB1 is required for adhesion-induced PAK1 activation at early time 
points, whereas Cdc42/Rac1 are more important at later time points.  Activation of PAK1 by 
CIB1 leads to decreased cell migration through the LIM kinase (LIMK)/cofilin pathway.  An 
interaction between CIB1 and PAK1 has been detected by solid-phase binding studies and by 
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αIIb
α2
α4
α5
αL
αM
αV
983 1008
Minimal CIB1-
binding sequence
LVLAMWKVGFFKR--------NR--P---PLEEDD-------EEGQ--  
LVAILWKLGFFKR---------KYEKMTKNPDEID----ETTELSS--  
ISYVMWKAGFFKR---------QYKSILQEENRRDSWSYINSKSNDD-  
LIYILYKLGFFKR--------SL--PYGTAMEKAQ---LKPPATSDA-  
IFIVLYKVGFFKRNLKEKMEAGRGVPNGIPAEDSE-QLASGQEAGDPG  
ITAALYKLGFFKR---------QYKDMMSEGGPP------GAEPQ---  
LVFVMYRMGFFKR--------VR--P---PQEEQEREQLQPHENGEG-  
Fig. 1.5.  Sequence alignment of α integrin cytoplasmic tails.  Alignment was created 
using ClustalW.  Sequences extend to the C-terminus for all α integrins shown except αL 
and αV.  Residues that are hydrophobic are colored red, acidic are blue, and basic are green.  
Black boxes represent the sequences used for yeast two-hybrid experiments in Naik et al., 
1997.  The minimal CIB1-binding sequence of αIIb is highlighted with critical residues 
denoted with black dots.  Residue numbers for αIIb are indicated.
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co-immunoprecipitation experiments with purified proteins.  Additional attempts to see a 
direct interaction, including gel filtration and isothermal titration calorimetry (ITC), were 
unsuccessful (unpublished data), indicating that the CIB1/PAK1 interaction might be indirect 
or of low affinity.  CIB1 might activate PAK1 by disrupting the dimer interface, like 
Cdc42/Rac, since one of the putative CIB1-binding regions on PAK1 is part of the PAK1 
dimer interface. 
 1.3.3 Presenilin 2 
 Presenilins 1 and 2 (PS1 and PS2) are ER membrane proteins that are mutated in 
autosomal dominant forms of early-onset familial Alzheimer’s disease (FAD).  Fifty different 
mutations, mostly missense mutations, of PS1 are commonly associated with FAD, while the 
two missense mutations identified in PS2 are rare in FAD.  Mutant PS1 and PS2 are involved 
in aberrant processing of β amyloid precursor protein, which is involved in the pathogenesis 
of FAD (Thinakaran, 1999).  Increased levels of a particular cleavage product of this protein, 
Aβ42, are found in brains of AD patients (Gravina et al., 1995;Miller et al., 1993), and, more 
specifically, in FAD patients (Scheuner et al., 1996).  The Aβ42 peptide is more likely to 
form neurotoxic aggregates than the Aβ40 peptide found in normal patients (Hilbich et al., 
1991).  In addition to Aβ42 aggregates, intracellular aggregates of the tau protein, called 
neurofibrillary tangles, are hallmarks of Alzheimer’s disease (AD).  Cells containing 
neurofibrillary tangles have increased levels of free and protein-bound Ca2+ (Murray et al., 
1992).  Additional data also implicates increases in Ca2+ in AD.  Increased intracellular Ca2+ 
levels were observed in PC12 cells with overexpressed PS1 (Guo et al., 1996), but the 
corresponding experiments have not been performed with PS2.  Increases in Ca2+ levels can 
be toxic to neurons, and Aβ42 aggregates increase neuronal sensitivity to Ca2+ treatment 
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(Mattson et al., 1992). 
 CIB1 bound a cytoplasmic loop (residues 264-303) of PS2 in yeast two-hybrid 
experiments but did not bind the highly homologous loop of PS1 (Stabler et al., 1999).  
When two residues of PS1 were mutated to the corresponding residues of PS2, binding was 
restored.  The CIB1-binding loop of PS2 is C-terminal to the two FAD-associated mutations 
of PS2, N141I and M239V (Fraser et al., 2000).  There is conflicting data on whether or not 
binding of CIB1 to PS2 is Ca2+-dependent.  Purified PS2 bound a CIB1 affinity column in 
the presence of 2 mM EGTA, suggesting binding of PS2 to CIB1 is Ca2+-independent 
(Blazejczyk et al., 2006).  However, previous data has shown that Ca2+ is difficult to remove 
from purified CIB1 (Shock et al., 1999), so CIB1 treated with EGTA might have still been 
Ca2+-bound.  A different study showed that binding of CIB1 to PS2 is Ca2+-dependent, since 
EF-hand mutants of CIB1 that cannot bind Ca2+ do not bind PS2 in yeast two-hybrid assays 
(Zhu et al., 2004).  This is of interest because elevations in Ca2+ levels have been associated 
with AD, and CIB1 binds Ca2+ at concentrations found in excited cells (Yamniuk et al., 
2004).  However, in addition to disrupting binding to Ca2+, the EF-hand mutations of CIB1 
used in the yeast two-hybrid experiments are likely to have disrupted binding to Mg2+, and 
binding of CIB1 to resting concentrations of Mg2+ is likely to be important for protein 
conformational stability (Weljie et al., 2003;Yamniuk, Vogel, 2005) and ligand binding 
(Yamniuk, Vogel, 2005).  In addition, it is possible that the residues mutated in the EF-hands 
were required for interacting with PS2, although it is unlikely because direct binding of 
ligands to EF-hands has not been observed in CIB1 homologs. 
 CIB1 expression analyzed by immunostaining or Western blotting of normal rat brain 
sections show low expression levels, although the quality of the antibody was not evaluated 
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(Blazejczyk et al., 2006).  Expression levels of PS2 were high in all the brain sections tested.  
The authors concluded that the low levels of CIB1, when compared with the high levels of 
the AD protein PS2, indicate that CIB1 is not important in AD.  However, these conclusions 
are unfounded since the experiments were only performed with normal, undiseased brain.  In 
brain sections taken from AD patients, immunostained sections showed lower CIB1 levels in 
than in normal patients, although differences were difficult to detect (Bernstein et al., 2005).  
Proteins identified to date that are associated with AD have higher levels than normal, so it 
does not appear that CIB1 is involved in AD.  However, additional study is necessary to 
determine if if the decreased levels of CIB1 in AD are significant and important to the 
pathology of the disease. 
 1.3.4 Fnk and Snk 
 CIB1 also binds FGF-inducible kinase (Fnk) and serum-inducible kinase (Snk), 
which are serine-threonine kinases of the polo family of cell cycle-associated kinases 
(Kauselmann et al., 1999).  Polo-like kinases (plks) are homologous to the Drosophila 
melanogaster polo protein, which was identified in a screen for mutants that affected mitotic 
spindle pole behavior (Sunkel, Glover, 1988). Plks share a conserved region of 30 amino 
acids called the polo-box, a phosphoserine- or phosphothreonine-binding domain that is 
required for substrate interaction, subcellular localization, and function (van de Weerdt, 
Medema, 2006). 
 Both Fnk and Snk are immediate early genes, with their mRNA levels peaking after 
mitogen addition (van de Weerdt, Medema, 2006).  Based on data from the Snk-/- mouse, 
Snk appears to be important in the cell cycle.  Snk-/- embryos show retarded development, 
and Snk-/- fibroblasts show decreased proliferation and delayed entry into S phase (Ma et al., 
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2003a).  In addition, Snk is required for centriole duplication in the S and G2 phases (Warnke 
et al., 2004).  It is suggested that Snk is a mitotic checkpoint protein by transctivation by p53.  
Like cells lacking wild-type p53, cells in mitosis lacking Snk are sensitive to 
chemotherapeutic agents (Burns et al., 2003).  In addition, extensive SNK gene silencing by 
methylation was observed in many B cell neoplasms, and reintroduction of Snk induced 
apoptosis (Syed et al., 2006). 
 Fnk was expressed at high levels in B cell neoplasms and might be compensating for 
the loss of Snk (Syed et al., 2006).  Overexpressed Fnk leads to apoptosis (Conn et al., 2000), 
and  Fnk activity increases in response to DNA damage and cellular stress (Xie et al., 
2001a;Xie et al., 2001b).  Fnk appears to lead to cell cycle arrest and apoptosis by 
phosphoylating p53 (Xie et al., 2001a) and Cdc25C (Roshak et al., 2000). 
 An interaction between CIB1 and both Fnk and Snk was first seen by yeast two-
hybrid assays, and the polo box of Fnk or Snk was sufficient for the binding to occur 
(Kauselmann et al., 1999).  Binding was also observed in co-immunoprecipitation 
experiments with purified proteins (Kauselmann et al., 1999) and overexpressed tagged 
proteins (Holtrich et al., 2000;Ma et al., 2003b).  Overexpressed CIB1 inhibits Snk kinase 
activity in Cos-7 cells (Ma et al., 2003b) 
 In rat hippocampal neurons, expression of CIB1, Fnk, and Snk displayed identical 
distribution to the somata and dendrites (Kauselmann et al., 1999).  Overexpressed CIB1 and 
Snk also colocalize in the cytoplasm of Cos-7 and Neuro2A (N2A) cells, a neuronal cell line.  
Overexpressed CIB1 localized to the nucleus and cytoplasm when expressed alone in Cos-7 
cells.  Co-expression of Snk and CIB1 caused CIB1 to be localized exclusively to the 
cytoplasm, suggesting Snk might participate in recruiting CIB1 from the nucleus to the 
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cytoplasm.  However, in a different study, co-expression of Snk and CIB1 did not result in a 
complete recruitment of CIB1 to the cytoplasm (Ma et al., 2003b).  Analysis of cell 
morphology showed that expression of CIB1 inhibited morphological changes induced by 
Snk.  Arborization, where multiple processes project from the cell body, and cell rounding 
occurred when Snk was expressed alone, but co-expression with CIB1 significantly 
decreased the occurrence of these morphological changes.  If CIB1 does significantly affect 
Snk and Fnk activity and function, it would be the first time CIB1 is implicated in cell cycle 
events.  This could have important implications in cancer. 
 1.3.5 IP3R 
 The inositol 1,4,5-trisphosphate receptor (IP3R) is a Ca2+ release channel localized to 
the endoplasmic reticulum.  This receptor is activated by IP3, a downstream signaling 
molecule of the G protein-coupled receptor/phospholipase C (PLC) β or tyrosine kinase 
receptor/PLC γ pathway (Berridge, 1993).  Recent data showed that in addition to being 
activated by IP3, the IP3R is activated by calcium binding proteins (CaBPs), CaM-like 
proteins that are specific to neurons (Yang et al., 2002).  CaM itself has been implicated in 
IP3R signaling (Cardy, Taylor, 1998;Kasri et al., 2006;Patel et al., 1997), although other 
studies do not corroborate these findings (Mak et al., 2003;White et al., 2006).  By looking 
for an IP3R regulatory protein like the CaBPs that is not specific to neurons, White and 
colleagues found that GST-CIB1 co-immunoprecipitates with the IP3R in a Ca2+-dependent 
manner (White et al., 2006).  In addition, WT CIB1 activates IP3R at early timepoints in in 
vitro experiments.  However, CIB1-transfected cells show decreased IP3R activation.  The 
same contrasting results were seen with CaBP, but not with control EF-hand-containing 
proteins.  It is suggested that prolonged exposure to CIB1 induces channel inactivation after 
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an initial activating effect.  The regulation of IP3R by binding small EF-hand proteins such as 
CIB1 and CaBPs represents a regulatory mechanism distinct from IP3 binding.  
 1.3.6 PDK1 
 Recent data suggest CIB1 interacts with 3-phosphoinositide-dependent protein kinase 
1 (PDK1)(Zhao et al., 2007), a regulator of the cAMP-dependent, cGMP-dependent, protein 
kinase C (AGC) family of protein kinases that includes protein kinase B (PKB/Akt).  PDK1 
is important in growth factor and insulin signaling through its phosphorylation and activation 
of AGC kinases.  An interaction between CIB1 and PDK1 was seen by co-
immunoprecipitation and solid-phase binding assays.  CIB1 activated PDK1 
autophosphorylation and phosphorylation of p90 ribosomal S6 kinase (RSK).  RSKs are 
important in promoting cell survival and proliferation by acting on substrates at the plasma 
membrane (Richards et al., 2001).  CIB1 did seem to participate in recruiting PDK1 to the 
plasma membrane, since unmyristoylated CIB1 or a CIB1 mutant unable to bind PDK1 
showed less membrane localization of PDK1 (Zhao et al., 2007).  Transfection of WT CIB1 
protected cells from apoptosis induced by sorbitol and cycloheximide.  A mutant of CIB1 
unable to bind PDK1 was unable to protect cells from apoptosis.  These data indicate CIB1 is 
part of an important cell survival pathway that might be a part of tumorigenesis.  Targeting 
CIB1 in tumor cells could be a useful cancer therapy. 
 1.3.7 hTERT and DNA-PK 
 .In most somatic cells, the telomeres of chromosomes shorten with each DNA 
replication cycle.  Telomerase is a reverse transcriptase that lengthens the telomeres of 
chromosomes in certain cell types.  The catalytic subunit of telomerase is comprised of 
human telomerase reverse transcriptase, hTERT, and an integral RNA (hTR).  It is unknown 
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what proteins regulate telomerase, although candidates such as TPP1 have been shown to 
activate it (Wang et al., 2007;Xin et al., 2007).  Normal somatic cells do not commonly 
express telomerase, but tumor cells show telomeres in tumor cells have decreased rates of 
shortening due to telomerase activity (Counter et al., 1992;Kim et al., 1994).  In addition, 
telomerase activity is induced by stress in certain neural cells, such as astrocytes (Baek et al., 
2004), neurons (Kang et al., 2004), and/or microglia (Flanary, Streit, 2004;Fu et al., 2002).  
 A recent study showed that CIB1 interacted with human telomerase reverse 
transcriptase (hTERT) in yeast two-hybrid and co-immunoprecipitation experiments (Lee et 
al., 2004).  In an epithelial breast cancer cell line, MCF7 cells, overexpressed CIB1 increased 
telomerase activity and telomere length (Lee et al., 2004).  CIB1 also binds another protein 
involved in telomere elongation, the catalytic subunit of DNA-dependent protein kinase 
(DNA-PKcs)(Wu, Lieber, 1997).  The catalytic subunit of DNA-PK is homologous to the 
phosphotidyl inositol-3-kinase (PI3-K) family of proteins but does not seem to have lipid 
kinase activity (Hartley et al., 1995).  The regulatory subunit of DNA-PK is comprised of the 
Ku70/80 subunits and binds DNA.  DNA-PK is known to be involved in DNA double-strand 
break repair, but it has recently been found to be involved in telomeric end stability (d'Adda 
et al., 2001;Gilley et al., 2001;Rebuzzini et al., 2004). 
 Studies are being performed to determine whether telomerase or telomerase-binding 
proteins can be targeted in cancer therapeutics (Zimmermann, Martens, 2007).  For treating 
neurogenerative diseases and stroke, it would be useful to have therapeutics that prevent 
telomere shortening and neural cell death (Zhang et al., 2007)  Additional study is required to 
determine the extent of CIB1 involvement in these events. 
1.4 CIB1 knockout mouse 
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 1.4.1 Male sterility 
 The most striking phenotype of the CIB1 null mouse is male sterility (Yuan et al., 
2006a).  CIB1 null mice grow normally, but the haploid phase of spermatogenesis is 
disrupted.  There is reduced testis size, decreased numbers of germ cells in the seminiferous 
tubules, increased germ cell apoptosis, and the loss of elongated spermatids and sperm. 
 1.4.2 Absence of platelet phenotype 
 Since in vitro data imply that CIB1 is an inhibitor of agonist-induced αIIbβ3 
activation, a hyperactive platelet phenotype was expected.  However, no bleeding defects 
were observed.  CIB1 null mice have normal thrombus formation, bleeding times, platelet 
spreading and aggregation, and αIIbβ3 activation (Jan DeNofrio, unpublished data).  Reasons 
for the discrepancy between these data and previous in vitro data could be a function of 
differences in the mature platelets used for CIB1 null characterization and the platelet 
precursor cells (megakaryocytes) used in previous experiments.  Finally, additional CIB1 
family members could be compensating for the loss of CIB1 in the CIB1 null mice. 
 1.4.3 Angiogenesis defect 
 The CIB1 null mouse also has an angiogenesis defect (Zayed et al., 2007).  They have 
decreased endothelial cell function, proliferation, and migration.  Upon ischemic injury, 
CIB1 null mice display decreased recovery and angiogenesis to damaged retina and hindlimb 
tissues.  CIB1 null mice also display decreased activity of PAK1 and ERK1/2, kinases that 
are involved in angiogenesis.  Microarray analysis showed that some tyrosine kinases were 
downregulated in CIB1 null cells.  In addition, there is decreased growth-factor induced 
matrix metalloproteinase expression and activity of MMP2 in the CIB1 null mouse. 
 1.4.4 Increased P-selectin and von Willebrand factor 
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 CIB1 null mice have increased plasma P-selectin and von Willebrand factor (vWF) as 
determined by Luminex analysis (Jan DeNofrio, unpublished data).  P-selectin is a plasma 
protein that is released from platelets or endothelial cells.  It binds the PSGL-1 receptor, 
which links platelets and stabilizes platelet aggregates.  P-selectin also facilitates leukocyte 
adhesion to activated platelets and endothelial cells.  Plasma P-selectin levels often positively 
correlate with thrombotic events.  The source of the elevated P-selectin in CIB1 null mice is 
unknown.  vWF is important in hemostasis by binding glycoprotein (GP) Ib-IX-V, thereby 
activating platelets.  vWF also interacts with Factor VIII and prevents its degradation, and it 
interacts with collagen on exposed endothelial cells. 
 1.4.5 Interpretation of CIB1 null mouse data to date 
 A hyperactive platelet phenotype was not seen in the CIB1 null mouse, possibly 
indicating that another protein(s) is compensating for the loss of CIB1 and its inhibition of 
αIIbβ3.  However, the additional phenotypes of the CIB1 null mouse indicates that the action 
of CIB1 on additional proteins is significant and worthy of study.  It is known that CIB1 
binds a number of serine-threonine kinases, and it is possible that CIB1 binds other α 
integrins, including α5.  In Chapter III, we will explore the interaction of CIB1 with 
additional α integrins.  If a high-affinity interaction with other α integrins is seen, it is 
possible that the lack of CIB1 in the CIB1 null mouse is responsible for some of the 
phenotypes.  Preventing integrin activation is a goal of therapeutics for coronary artery 
disease, cancer, and autoimmune diseases.  Characterizing the interaction of CIB1 with α 
integrins and how CIB1 acts on these integrins will provide an additional avenue for the 
development of therapeutics. 
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2.1.  Introduction 
 CIB1 is a small EF-hand-containing protein that binds Ca2+ at EF3 and EF4 
(Yamniuk et al., 2004).  It is homologous to calcineurin B (CnB)(28% identity) and the 
neuronal calcium sensor (NCS) family of proteins (~23% identity).  Homology-based 
modeling generated from the structures of CnB and recoverin, an NCS protein, shows many 
shared features between CIB1 and its homologs (Barry et al. 28877-83).  Like CnB and NCS 
proteins, the two lobes of CIB1 are in a fixed orientation with respect to one another 
(Yamniuk et al., 2006).  This is in contrast to calmodulin (CaM), which has a highly flexible 
linker between its two lobes. 
 The NCS family, which includes recoverin, KChIP1, and frequenin, is exclusively 
neuronal and shares a high degree of homology among family members (Burgoyne, Weiss, 
2001).  Many critical residues are highly conserved within the family.  Some NCS proteins 
are myristoyl-switch proteins, although some, like frequenin, have a myristoyl group that is 
constitutively extruded from the interior of the protein.  Many NCS proteins dimerize in the 
presence or absence of Ca2+ or ligand. 
 Unlike NCS proteins, CIB1 is ubiquitously expressed.  CIB1 shares less homology 
with NCS proteins than they do with one another, and conserved residues of the NCS family 
are not found in CIB1.  Though myristoylated, CIB1 is not a Ca2+-myrisotyl switch.  The 
dimerization status of CIB1 is unknown.  CIB1 shares more homology with CnB than with 
NCS proteins, although unlike CnB, it is not known to be a regulatory subunit of a 
phosphatase. 
 The sequences of three CIB1 homologs (CIB2, 3, and 4) are also found in the human 
genome.  CIB1 and some of its homologs have been identified in other vertebrates, and 
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highly homologous sequences are present in the genome of more simple organisms such as 
Drosophila melanogaster.  Sequence analysis indicates CIB1 and its homologs form a 
protein family distinct from those of the CnB and the NCS families.  To help determine the 
molecular mechanism for CIB1 binding to its various targets, this chapter details the x-ray 
crystal structure of Ca2+ -bound CIB1 to 2.0 Å. 
2.2 Materials and Methods 
 Protein Purification − Human wild type CIB1 and CIB1 ∆1-8 (residues 9-191), each 
fused to an amino-terminal hexahistidine tag, were expressed from pProEX HTc (Invitrogen) 
in E. coli BL21(DE3) cells.  The final gene sequence includes a hexahistidine Ni-affinity tag 
followed by a tobacco etch virus (TEV) cleavage site at the N-terminus; the tag was later 
removed from the protein as described below.  CIB1 ∆1-8 was used for crystallization 
experiments.  Wild-type CIB1 was used for gel filtration and analytical ultracentrifugation 
experiments. 
 Expression of CIB1 was initiated by inoculating one liter of LB broth with 100 ml 
overnight culture and incubating at 37º C.  CIB1 expression was induced after 4 h by the 
addition of IPTG to a final concentration of 1 mM, and cells were incubated for an additional 
3 h at 37º C.  Cells were centrifuged at 2000 g for 20 min and resuspended in Buffer A, 
composed of 20 mM Tris, 10 mM imidazole, 100 mM NaCl, 10% (v/v) glycerol, and 100 µM 
CaCl2 (pH 7.5) with 1 tablet of “Complete EDTA-free protease inhibitor cocktail” (Roche).  
Cells were lysed by one pass through an EmulsiFlex-C5 (Avestin) homogenizer, and lysed 
cells were centrifuged at 200,000 g for 40 min.  Clarified cell lysate was loaded onto two 5 
ml Hi-Trap chelating HP columns in series (Amersham Pharmacia) that had been preloaded 
with 100 mM NiSO4 and equilibrated with buffer.  The column was washed with 5% and 
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30% of Buffer B (Buffer A plus 1 M imidazole) and CIB1 was eluted at 30% of this buffer.  
Fractions containing CIB1 were pooled and dialyzed 1 h in 20 mM Tris, 10 mM NaCl, 10% 
(v/v) glycerol, and 100 µM CaCl2 (pH 7.5) in order to dilute the imidazole and remove 
residual Ni2+.  Dialysis and removal of the His-tag was performed by overnight incubation 
with 4 ml TEV, purified as stated previously (Parks et al., 1995), in dialysis buffer that also 
contained 5 mM DTT.  Analysis of the extent of cleavage was performed by analyzing 
samples by SDS-PAGE.  If further cleavage was required, incubation with additional TEV 
was performed.  CIB1 was further purified by an S-200 gel filtration column (Amersham 
Pharmacia) equilibrated with 20 mM Tris, 150 mM NaCl, and 5 mM DTT (pH 7.5).  
Fractions were analyzed by SDS-PAGE and the purest fractions were concentrated using a 
Vivaspin 10 MWCO concentrator (Vivascience, Hannover, Germany) and the buffer 
exchanged to 20 mM MES pH 6.5, 10 mM NaCl, 2 mM DTT (pH 6.5) by several rounds of 
dilution and concentration.  Protein was frozen in 50 µl aliquots at 30 mg/ml.  Quantities of 
40-50 mg of protein were obtained per liter of broth.  
Crystallization − Crystals of purified CIB1 ∆1-8 were obtained by sitting drop vapor 
diffusion at 18ºC for 3-5 days by equilibrating against 20 mM Bis-tris propane (BTP), 300 
mM calcium acetate, and 18% PEG 3350 (pH 6.8) and reached full size after 10 days.  
Crystals were cryoprotected by slowly equilibrating the crystal drop to glycerol in increments 
of 2%, 4%, 6%, 8%, 10%, 15%, and 20% (v/v) glycerol in the mother liquor solution, 
followed by flash-freezing in liquid nitrogen. 
 Gel Filtration − The “Low Molecular Weight Gel Filtration Calibration Kit” 
(Amersham Pharmacia) was used to calibrate a Superdex S-75 gel filtration column 
(Amersham Pharmacia) according to manufacturer’s instructions.  Briefly, 200 µl each of 
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ovalbumin (43 kD) and ribonuclease A (13.7 kDa) at 5 mg/ml or albumin (67 kDa) and 
chymotrypsinogen A (25 kDa) were loaded onto a column pre-equilibrated with S-75 buffer 
(20 mM Tris pH 7.5, 150 mM NaCl, 1 mM DTT, and 2 mM calcium acetate) at 0.8 ml/min.  
The void volume (Vo) was determined by the elution volume of blue dextran (2000 kDa).  
Purified full-length CIB1 (250 µL of 4 mg/ml) was loaded onto the column that had been 
pre-equilibrated with 2 mM calcium acetate or 2 mM EGTA.  The cytoplasmic αIIb peptide 
(Ac-LVLAMWKVGFFKRNRPPLEEDDEEGQ-COOH) was added to CIB1 in a molar ratio 
of 2:1, with 200 µl CIB1 (65 µM) and 100 µl αIIb (146 µM) loaded. 
 Analytical Ultracentrifugation (AUC) − Purified full-length CIB1 was equilibrated 
to AUC buffer (20 mM Tris pH 7.5, 150 mM NaCl, and either 2 mM (CH3COO)2Ca or 2 
mM EGTA) using a Vivaspin 10 MWCO concentrator (Vivascience, Hannover, Germany).  
The final concentrations of CIB1 were ~230, ~180, and ~80 µM, with A280  values of 
approximately 0.6, 0.4, and 0.2.  For experiments with the cytoplasmic αIIb peptide (Ac-
LVLAMWKVGFFKRNRPPLEEDDEEGQ-COOH), a 1:1 molar ratio of αIIb to CIB1 was 
used.  Equivalent concentrations of αIIb peptide were used in the sample and reference cells.  
Prior to centrifugation, low molecular weight impurities in the αIIb peptide were eliminated 
by performing a buffer exchange in a stirred cell (Amicon) with a 1,000 NMWL 
Ultrafiltration Membrane (Millipore) of regenerated cellulose.  Analytical ultracentrifugation 
was performed using a Beckman Optima XL-I Ultracentrifuge, a Ti-60 rotor and a 6-sector 
cell (1.2 cm path length).  For CIB1 protein alone, samples were centrifuged at 16,000 rpm 
for 26 h at 20° C.  Offset was determined by meniscus depletion by centrifugation at 45,000 
rpm for 6 h.  For CIB1 + αIIb samples, centrifugation was performed at 16,000 rpm for 32 h 
at 20° C, and offset was determined by centrifugation at 40,000 rpm for 8 h.  Equilibrium 
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was determined to have been reached when data collected every 2 h did not change from the 
previous reading.  Data were fit using XL-A/XL-1 Data Analysis Software Version 4.0 
(Beckman Instruments, Inc., 1997) using values of 0.736 for the partial specific volume and 
1.0 for solvent density. 
 Data collection − The data used for phasing by single-wavelength anomalous 
diffraction (SAD) were collected from a single crystal of CIB1 on a Rigaku RU-H3R rotating 
anode X-ray generator fitted with a chromium anode and Osmic VariMax-Cr optics, which 
together generate Cr Kα radiation, (λ =  2.29 Å) and a Rigaku R-AXIS IV imaging plate area 
detector.  Chromium Kα radiation is more suitable than Cu Kα (λ=1.54 Å) for detecting the 
dispersion signal from intrinsic elements such as calcium and sulfur of CIB1 protein, since 
the signal is doubled (∆ƒ″=2.51 e- and ∆ƒ″=1.14 e-, respectively) compared to that of Cu Kα 
(∆ƒ″=1.29 e- and ∆ƒ″=0.56 e-, respectively).  The VariMax-Cr was equipped with a slit that 
allowed the divergence to be tuned for the sample.  This slit setting was optimized by 
maximizing I/σ(I) on equivalent screening images.  The crystal was mounted in an arbitrary 
orientation and data was collected at cryogenic temperatures in a single continuous scan.  
Both incident and diffracted beam helium beam paths were used to minimize air absorption 
and scattering.  Data collection statistics are given in Table 1. 
 For phasing, we collected 510° of data to ensure high redundancy for the calcium and 
sulfur anomalous signal, although with the chromium wavelength X-rays, this much 
redundancy is probably not necessary (Yang et al., 2003).  Data were processed with 
HKL2000 (38), which has an absorption correction that is needed for the longer wavelength 
chromium X-rays (Yang et al., 2003).  Due to the longer wavelength and the necessity to use 
the R-AXIS IV detector with a 300 mm image plate width, the crystal-to-detector distance 
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was 122 mm, and the maximum resolution for this data set was 2.7 Å.  The structure was 
refined against data collected from another crystal collected at the SER-CAT beamline at the 
Advanced Proton Source (APS) at 1.0 Å wavelength; this crystal diffracted to 2.0 Å. 
 Structure determination and refinement − Matthews coefficients indicated two 
CIB1 molecules per asymmetric unit in the P21 cell.  The program SOLVE (Terwilliger, 
Berendzen, 1999) was used to locate the positions of anomalous scatterers from the 
chromium data.  We used the “SAD” script (to 3.0 Å) provided on the SOLVE website to 
search for the 8 highest peaks, reasoning that these might correspond to individual calcium 
ions (with a higher ∆f´´ at 2.2909 Å compared to sulfur) bound to each of the EF-hands in the 
asymmetric unit.  SOLVE easily found 8 sites with occupancies ranging from 0.147 to 0.522.  
The overall Z score from SOLVE was 30.9, and the figure of merit (FOM) was 0.39.  Only 
two, C-terminal EF-hands per CIB1 monomer are occupied by individual calcium ions.  
There are, however, two more calcium ions per CIB1 monomer that bind at surface positions 
and are most likely due to the high Ca2+ concentration (300 mM) in the crystallization 
medium.  That gives a total of eight calcium ions in the asymmetric unit.  The top 8 sites 
found by SOLVE were not all calcium ions; three of these were actually sulfur atoms. 
 The program RESOLVE (Terwilliger, 2000) was used to find non-crystallographic 
symmetry and carry out “statistical” solvent flattening.  Three pairs of the 8 sites were related 
by NCS; and the “overlap of NCS-related density” was 0.76 in RESOLVE.  The solvent 
flattened electron density map from RESOLVE was used to trace the chain of one of the two 
monomers of CIB1 in the asymmetric unit.  The process was guided by the structure of 
calcineurin B (PDB code 1TCO), which is 57% homologous to CIB1.  The sequence in the 
helices surrounding the EF-hands was matched easily to density; however, the density in the 
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EF-hand loops was not as continuous and clear.  An anomalous difference Fourier map using 
the phases from the eight SOLVE sites produced a new set of sites, which turned out to be 
sulfur and lower occupancy calcium atoms.  The chain tracing was verified using the sulfur 
sites from cysteine and methionine residues.  Once a preliminary model of the first molecule 
in the asymmetric unit was built, molecular replacement using the CCP4 program AMoRe 
(Collaborative Computational, 1994) was used to position the second molecule.  The 
independently determined positions of calcium and sulfur atoms determined by SOLVE 
verified this solution. 
 The density for the second molecule is significantly weaker, especially in the second 
half of the molecule that contains the two EF-hand calcium ions.  The temperature factors for 
this molecule in initial rounds of conjugate gradient or simulated annealing refinement using 
CNS (Brunger et al., 1998) were quite high (average temperature factors for all atoms in 
molecule 1 and 2 were typically ~40 and ~70, respectively).  Rfree values were just below 
30% for these refinements, using either the 2.0 Å data set collected at the synchrotron, or the 
chromium data set to 2.8 Å.  If the packing is inspected, the second molecule (“B”) has fewer 
intermolecular contacts in the crystal, apparently giving it a more flexible position and 
thereby more average disorder as indicated by high temperature factors.  A TLS refinement 
using the CCP4 program Refmac5 (39) to 2.0 Å using each subunit and its associated 
calcium ions as a TLS “group”, and using tight geometrical restraints (matrix diagonal 
weighting term = 0.05) gave a model with Rwork = 21.2% and Rfree = 25.7%.  The RMS bond 
and angle deviations are 0.01 and 1.10, respectively.  From the Ramachandran plot, 2 (0.6%) 
and 1 residues (0.3%) were found in generously allowed and forbidden regions respectively; 
however, these residues are either at the N-terminus (residues 13 and 14 in molecule A) or 
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neighboring a disordered loop (residue 146 in molecule B) where the density is poor. 
 Sequence Alignment − Sequences represented in Fig. 2.3 were aligned using 
ClustalX (Thompson et al., 1997), and the output guide tree file was imported and displayed 
as a dendrogram in Fig. 2.4 using the program TreeView 1.6.6 
(http://taxonomy.zoology.gla.ac.uk/rod/rod.html). 
2.3  Results 
 2.3.1 Overall structure of CIB1 and geometry of Ca2+ binding 
 Full-length CIB1 consistently yielded twinned, poorly formed crystals.  Since 
proteins homologous to CIB1, such as recoverin, have a disordered N-terminus (Flaherty et 
al., 1993) and secondary structure indicates that this region is also disordered in CIB1, CIB1 
∆1-8 was used for crystallization and structure determination (Fig. 2.1).  Molecular 
replacement using the CIB1 homologs recoverin, CnB, CaM, or a  previous CIB1 model 
provided unsuitable R factors around 48%, so the structure of CIB1 was solved by SAD 
phasing using chromium radiation (λ=2.29 Å)(Rigaku/MSC Inc., The Woodlands, TX).  
These data were collected to 2.7 Å, but phases were eventually extended to 2.0 Å using 
native data sets collected both in-house and at the SER-CAT beamline at Advanced Photon 
Source (APS; Argonne, IL).  There are two molecules of CIB1 in the asymmetric unit.  The 
electron density (Fig. 2.2A) has been fit with models of CIB1 encompassing residues 12-191 
except for a disordered loop between residues 137-142 in molecule A and 136-145 in 
molecule B. 
 The overall fold of CIB1 is shown in Fig. 2.2B, and is very similar to other Ca2+-
binding proteins containing four EF-hands, such as calmodulin and calcineurin B.  However, 
we observed that only EF-hands 3 and 4 of CIB1 bound Ca2+ (Fig. 2.2B,C), as previously 
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Fig. 2.1.  Purification and crystallization of CIB1.  (A)  WT CIB1 (1 µl and 2 µl) 
purified as described in section 2.2 was subjected to SDS-PAGE and stained with 
coomassie blue.  Comparable purity was obtained for CIB1 ∆1-8.  (B)  Crystal of CIB1 ∆1-
8 in 20 mM BTP, 300 mM calcium acetate, and 18% PEG 3350 (pH 6.8).
1 µl           2 µl
750 µm
A.                                                      B.
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Fig. 2.2.  Electron density map, overall fold, and EF-hand geometry of CIB1.  (A) Electron density from 
EF-hand 4 in CIB1.  The 2Fo - Fc electron density omit map (shown in stereo, contoured to 1 σ) was calculated 
by removing all atoms within 10.0 Å of the coordinating Ca2+ ion.  Highlighted are seven ligands that 
coordinate the Ca2+ ion with a pentagonal bipyramidal geometry typical of EF-hands.  Equatorial ligands 
include the side-chain carboxylates of Asp-161, Asp163, Asp-165, and Glu-172, and the carbonyl oxygen (O) 
of Thr-167, while axial ligands are provided by the remaining oxygen of the carboxylate group of Glu-172 and 
a water molecule.  (B) Ribbon diagram of the overall fold of CIB1 showing the positions of the high-affinity 
Ca2+ ions (gold spheres) bound to EF-hands 3 and 4.  Regions are color-coded:  N-terminal region and EF1 are 
blue, EF2 is yellow, EF3 is red, EF4 is green, and the C-terminal helix is purple.  Helices as well as the termini 
are labeled;  a dotted line indicates the disordered loop between helices H7 and H8.  (C) Ribbon diagram of 
EF-hands 1 through 4, underneath which are worm diagrams of the EF-hands showing individual amino acids 
involved in Ca2+ binding for EF3 and EF4, and possible Ca2+-binding amino acids based on their position 
(positions 1, 3, 5, 7, 12, and 13) in the EF2 loop.  Because the conformation of EF1 is degenerate, no worm 
diagram is shown.  In this diagram, relevant protein oxygens and waters are red.  Dashed lines indicate Ca2+ 
ligation or hydrogen bonding.
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________________________________________________________________________ 
Source                  chromium   APS 
λ (Å)                   2.29    1.00 
Space group                 P21    P21
Unit cell (Å)                  56.61, 50.98, 77.13 
    (°)                 90, 103.128, 90 
Rotation range (°)                510    360 
Resolution (Å)                40 - 2.6   40 - 2.0 
Reflections      633,650   589,209 
Unique reflections     12,013   29,442 
R(I)merge2 (%)                 4.6 (12.6)1   5.8 (23.4) 
Completeness (%)                94.1 (88.1)   95.4 (81.0) 
Redundancy                 10.4 (8.4)   7.3 (6.2) 
<I/σ(I)>                 54.0 (14.5)   32 (5.8) 
Data processing     HKL2000   HKL2000 
Anomalous scatterers per A.U.3   8 Ca, 3 S 
Calculated anomalous <∆F>/<F> (%)  3.7  
________________________________________________________________________ 
Resolution (Å)  40 - 2.0 
Number of protein atoms 2781 (2 molecules / A.U.) 
Number of waters  397 
F/σF cutoff   0  
Rcryst4    21.2% (24.4) 
Rfree4    25.7% (30.2) 
R.m.s.d. bonds (Å)  0.01 
R.m.s.d. angles (°)  1.10 
Ramachandran plot 
% in most favored regions  92.5 
% in additional allowed regions 6.6 
% in disallowed regions  0.3 
 
________________________________________________________________________ 
1Values in parentheses are for the outermost resolution shell. 
2R(I)merge =  Σ hkl│I - <I>│ Σ I, where I is the observed intensity and <I> is the average intensity from 
observations of symmetry related reflections, respectively. 
3A.U. – asymmetric unit. 
4Rcryst and Rfree  =  Σ ║Fo│-│Fc║/ Σ│Fo│, where 5% of the reflections were held aside for Rfree throughout 
refinement. 
 
 
 
Table 2.1.  Data collection and refinement. 
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demonstrated by NMR (Yamniuk et al., 2004).  Calcium ions bind canonical EF-hands with 
high affinity due to acidic residues at positions 1, 3, 5 and 12, where residues at positions 1, 3 
and 5 contribute individual ligands to the coordination sphere and the residue at position 12 
contributes two ligands (Michiels et al., 2002).  In most EF-hands, a backbone carbonyl at 
position 7 as well as a water molecule that is hydrogen-bonded to a sidechain oxygen from 
position 7 complete the coordination sphere, yielding a pentagonal bipyramidal geometry.  In 
EF4 of CIB1 (Fig. 2.2C), the side chains of Asp 161 (position 1), Asp 163, Asp 165, and Glu 
172 (position 12) coordinate Ca2+, with Glu 172 being a bidentate ligand.  Thr 167 (position 
7) ligates Ca2+ through its carbonyl oxygen and also coordinates a water molecule that ligates 
Ca2+.  Similarly, in EF3 (Figure 2.2C), the Ca2+ is coordinated by the side chains of Asp 116 
(position 1), Asp 118, Asp 120, and Asp 127 as well as the carbonyl of Thr 122 (position 7) 
and two water molecules.  One ligating water molecule is bridged through an additional 
water molecule interacting with the side chain of Thr 122, and the other ligating water 
molecule is seen in only one molecule of the asymmetric unit.  In EF4, this water molecule is 
replaced by the bidentate ligation of Glu 172 (position 12).  Relative to EF4, the ligation 
sphere of the Ca2+ in EF3 is less well ordered, which is consistent with the fact that EF3 
binds Ca2+ with a lower affinity than EF4 (Yamniuk et al., 2004). 
 Calcium ions are not bound in EF1 and EF2.  It is not surprising that Ca2+ is absent 
from EF1, because it has an additional eight amino acids within the loop that normally binds 
Ca2+.  Following this extended loop region in EF1, the helix that typically corresponds to the 
second helix in an EF-hand is kinked at Pro 62, a residue conserved in calmodulin and 
calcineurin B, thereby creating two smaller helices (H3a and H3b)(Fig. 2.2C).  EF2 is less 
radically modified from a canonical EF-hand domain.  However, many of the residues 
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(positions 1, 3, and 5) within the loop that are typically acidic and chelate calcium ions have 
been replaced with serine or alanine.  The EF2 loop also contains 13 residues rather than 12, 
with the extra residue, Pro 82, inserted after position 3. 
 A high concentration of Ca2+ (300 mM calcium acetate) was necessary for 
crystallization, presumably explaining why each monomer of CIB1 binds an additional two 
Ca2+ ions in positions not typically associated with EF-hand domains (see Table 2.1).  There 
are six water molecules in the octahedral coordination sphere of each of these Ca2+ ions, 
indicating that both binding events are of low affinity and most likely not biologically 
relevant, which is consistent with previous binding data (Yamniuk et al., 2004). 
 The helices of EF-hands reorient in relation to one another when Ca2+ is bound (Yap 
et al., 2002).  The interhelical angle between the E and F helices is used as a measure of 
whether these helices display a Ca2+-bound (open) conformation or a Ca2+-free (closed) 
conformation.  In a closed conformation, E and F helices are close to one another and the 
interhelical angle (180° – θ) is large.  In an open conformation, when Ca2+ is present, the E 
and F helices are typically farther apart and the interhelical angle is smaller.  For example, 
Ca2+-free calmodulin has interhelical angles between 130° and 140°, while Ca2+-bound 
calmodulin has interhelical angles between 85° and 100° (Zhou et al., 2004).  In order to 
determine whether the EF-hands of CIB1 displayed an open or closed conformation, we 
calculated the interhelical angles using the program interhlx (Yap et al., 2002).  EF2, EF3, 
and EF4 of CIB1 display similar interhelical angles, with values of 116.4°, 113.2°, and 
111.5°, respectively.  Since these angles are so similar, they indicate that EF2, which does 
not contain Ca2+, adopts an open conformation like those of Ca2+-bound EF3 and EF4.  EF1, 
which is highly degenerate, has an interhelical angle of 125.5°, which is indicative of a more 
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closed conformation. 
 2.3.2 CIB1 and its structural relationship to other EF-hand containing proteins 
 To compare the structure of CIB1 to other EF-hand-containing proteins, the 
coordinates of CIB1 (the first molecule in the asymmetric unit) were compared to other 
proteins in the Protein Data Bank using MSD-fold (http://www.ebi.ac.uk/msd-srv/ssm/).  As 
expected, a number of mammalian EF-hand containing proteins showed significant 
homology to CIB1, the two most significant being calcineurin B (PDB code 1TCO, Z-score 
of 5.2, RMSD of 2.5 Å over 136 residues, 27% sequence identity) and KChIP1 (Z-score of 
3.9, RMSD of 2.6 Å over 136 residues, 24% sequence identity).  The structural alignment of 
these proteins based on the output from MSD-fold is shown in Figure 2.2A and 2.2B.  In 
addition to these proteins, an Arabidopsis protein (AtCBL2, PDB code 1UHN)(Nagae et al., 
2003) was found to have strong structural homology to CIB1 (Z-score of 5.1, RMSD of 2.4 
Å over 137 residues, 24% sequence identity).  This protein is part of a distinct calcineurin B-
like family of Arabidopsis proteins that interact with a novel family of plant serine/threonine 
protein kinases (Kudla et al., 1999). 
 Although CIB1 closely aligns to other EF-hand containing proteins in EF2, EF3, and 
EF4, significant differences appear within EF1 and the N-terminal region.  As stated 
previously, CIB1 contains a long insertion within the EF1 loop that is not found in any of the 
structures of EF-hand-containing proteins solved to date, including calcineurin B and 
KChIP1.  The geometries of helices H3a and H3b (Fig. 2.2C), including the bend of the 
helices due to the proline residue previously described, are recapitulated in calcineurin B (but 
not in KChIP1); this proline residue causes a kink in these helices that is also conserved in 
calmodulin.  However, due to the large insertion in the EF1 loop, helices H3a and H3b in 
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CIB1 & calcineurin B
CIB1 & KChIP1
Fig. 2.3.  Superposition of CIB1 with its closest structural homologs.  (A) Superposition 
of CIB1 with calcineurin B (PDB code 1TCO).  (B) Superposition of CIB1 with KChIP1 
(PDB code 1S6C).  N and C termini are labeled, and the different regions are colored 
according to the scheme in Fig 2.1, with the ribbons for calcineurin B and KChIP1 being 
semi-transparent.
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CIB1 do not superimpose on the equivalent helices in calcineurin B, despite the similar 
proline-induced helical break. 
 The N-terminal regions of calcineurin B and NCS proteins point away from the center 
of the molecule, but the equivalent portion of CIB1 points to the center of the protein and 
forms a number of interactions with helix H5 and H6 (Fig. 2.3).  As crystal packing 
interactions also occur in this region and the temperature factors for the N-terminus are 
generally higher than in the helices of the EF-hands, it is not clear if this conformation of the 
N-terminus is biologically significant. 
 Finally, the C-terminus of CIB1 forms an α-helix that is similar in position to the C-
terminal helix of KChIP1 (Fig. 2.3).  Since the C-terminus plays an important role in target 
recognition both in calcineurin B and in KChIP1, this region will be discussed in greater 
detail in Section 2.3.5. 
 2.3.3  Sequence alignment 
 Several proteins in the sequence database from arthropods to humans share 
significant sequence homology to CIB1.  Three proteins in humans with high homology to 
CIB1 are CIB2 (also known as KIP2), CIB3 (also known as KIP3), and CIB4, which share 
37%, 40%, and 44% identity, respectively.  There is no functional data about CIB3, and only 
the expression profile and chromosomal location have been determined for CIB2 (Seki et al., 
1999).  CIB4 is named by the present authors based on a sequence from automated 
computational analysis of the human genome (NCBI accession # XP_059399). 
 Based on the sequence alignment (Fig. 2.4), all CIB homologs have a large insertion 
within EF1, strongly suggesting that this EF-hand cannot bind Ca2+ in any of the CIB 
homologs.  Similarly, all CIB homologs contain a proline equivalent to Pro 62 of CIB1 that 
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Fig. 2.4.  Sequence alignment of CIB1.  CIB1 is aligned with its three human homologs 
(CIB2, CIB3, and CIB4), calcineurin B and two NCS proteins, KChIP1 and frequenin.  
Alignment of CIB1 with CIB2, CIB3, and CIB4 was performed using Clustal X (Thompson 
et al, 1997) and then merged with the structural alignment from MSD-fold 
(www.ebi.ac.uk/msd-srv/ssm/) of CIB1 with calcineurin B (PDB code 1TCO), KChIP1 
(PDB code 1S6C), and human frequenin (PDB code 1G8I).  The positions of helices (red 
tubes), loop regions (gray lines), and disordered regions (gray dotted lines) in the CIB1 
structure are shown above the alignment, and every tenth residue in CIB1 is marked by a 
dot above the alignment.  Residues in CIB1 involved in Ca2+ binding are colored red, and 
residues that correspond to the CIB1 hydrophobic binding pocket (see Fig. 2.6) and that are 
involved in dimerization in KChIP1 are highlighted with yellow and green circles, 
respectively.
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causes a kink between helices H3a and H3b (Fig. 2.4), which is important for the overall 
structure of the hydrophobic binding pocket (see Section 2.3.5). 
 However, one notable difference among CIB homologs is that the EF2 loop (between 
helices H4 and H5) of CIB2 and CIB3 contains more acidic residues than CIB1, indicating 
that CIB2 and CIB3 may each bind an additional Ca2+ ion within this region.  Differences in 
the number of bound Ca2+ ions among homologous proteins are not surprising, in that 
differences in Ca2+ stoichiometry are also observed among members of the NCS family.  For 
example, KChIP1 binds Ca2+ ions in EF-hands 3 and 4 (Zhou et al., 2004), recoverin binds 
Ca2+ ions in EF-hands 2 and 3 (Ames et al., 1997), and frequenin binds Ca2+ ions in EF-
hands 2, 3 and 4 (Bourne et al., 2001). 
 The dendrogram in Figure 2.5 depicts the sequence relatedness of CIB1 and its 
homologs, as well as a number of other mammalian Ca2+-binding proteins.  From this 
analysis, we conclude that CIB-like proteins, found in species from arthropods to humans, 
form a family distinct from both the calcineurin B-like and NCS proteins.  Members of the 
CIB family share closest homology to calcineurin B and its relatives, but sequence homology 
is still quite low between CIB family members and calcineurin B (~30% sequence identity).  
Among the four human CIB proteins, CIB2 and CIB3 are more ancestral, since CIB proteins 
from Drosophila melanogaster, Anopheles gambiae and Danio rerio more strongly resemble 
these proteins. 
 2.3.4 Oligomeric state of CIB1 
 Many NCS homologs of CIB1 form dimers or tetramers under various conditions.  
For instance, KChIP3 tends to form tetramers at protein concentrations higher than 20 µM 
and stable dimers at low protein concentrations (Osawa et al., 2001).  Similarly, neurocalcin 
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Fig. 2.5.  Evolutionary relationship of CIB1 with other Ca2+-binding proteins.  The 
dendrogram (derived as described in Section 2.2) is colored to highlight the distinct families 
of CIB-like proteins (purple), calcineurin B-like proteins (blue), and NCS proteins (green).  
The proteins are human unless otherwise stated, and their NCBI accession numbers are 
included.
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forms a dimer in the crystal (Vijay-Kumar, Kumar, 1999) and in solution when Ca2+ is 
present (Olshevskaya et al., 1999), but forms a monomer when Ca2+ is absent (Olshevskaya 
et al., 1999).  Conversely, GCAP-2 forms dimers in the absence of Ca2+ and monomers in the 
presence of Ca2+ (Olshevskaya et al., 1999).  Also, unmyristoylated recoverin forms a dimer 
within the asymmetric unit of the crystal structure (Flaherty et al., 1993), while KChIP1 also 
forms dimers, but only in the presence of ligand (Zhou et al., 2004).  Residues involved in 
KChIP1 dimerization are poorly conserved in CIB1 (Fig. 3A). 
 To determine whether CIB1 forms oligomers in the presence or absence of Ca2+ and 
ligand, we performed gel filtration.  In the presence of Ca2+, CIB1 eluted at a volume 
corresponding to 30.6 kDa, which is larger than its molecular weight of 21.7 kDa, but smaller 
than the expected size of a dimer, which would be 43.4 kDa (Fig. 2.6A).  The anomalous 
elution volume of CIB1 may be accounted for since gel filtration columns are typically 
calibrated using spherical proteins as standards, while EF-hand containing proteins have a 
more oblong “dumbbell-shape”.  Similarly, GCAP-2, which has a molecular weight of 23.8 
kDa, exhibits an anomalous elution volume, with the monomer eluting at 30.6 kDa and the 
dimer eluting at 57 kDa (Olshevskaya et al., 1999).  Apo-CIB1, or CIB1 in the absence of 
Ca2+, elutes with a larger molecular weight (32.5 kDa) than that of Ca2+-CIB1.  This is 
consistent with NMR data of apo-CIB1 showing that its conformation is more extended than 
that of Ca2+-CIB1 (Yamniuk et al., 2004).  An extended conformation is also seen in Ca2+-
free recoverin, as opposed to its more compact conformation when Ca2+ is present (Ames et 
al., 1997).  Ca2+-CIB1 in the presence of the entire αIIb cytoplasmic peptide eluted at 35 kDa, 
which is representative of the molecular weight of monomeric CIB1 plus the molecular 
weight of the peptide (3.1 kDa). 
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Fig. 2.6.  CIB1 primarily forms monomers in the presence or absence of Ca2+ and 
the αIIb cytoplasmic domain.  (A) Elution profiles of apo-CIB1, Ca2+-CIB1, and 
Ca2+-CIB1 plus αIIb cytoplasmic tail peptide were determined using a Superdex S-75 
column (Amersham Biosciences).  The molecular mass standards used were albumin 
(67 kDa), ovalbumin (43 kDa), chymotrypsinogen A (25 kDa), and ribonuclease A (13.7 
kDa).  The elution volume (Ve) of blue dextran was used to determine the void volume 
(Vo).  (B) Sedimentation equilibrium data of Ca2+-CIB1, apo-CIB1, and Ca2+-CIB1 
plus αIIb by analytical ultracentrifugation.  Molecular weights fit using a one-state 
model are posted on each graph.
58
 To confirm the gel filtration results, we performed sedimentation equilibrium of 
purified recombinant full-length CIB1 in the presence of either 2 mM (CH3COO)2Ca or 2 
mM EGTA by analytical ultracentrifugation (AUC).  These experiments were also performed 
in the presence of the αIIb peptide, with high, medium, and low concentrations of CIB1 as 
described in Section 2.2.  Molecular weight determinations are given for the medium 
concentration (150-190 µM), and the other concentrations give similar results.  The AUC 
data fit to a molecular weight for Ca2+-CIB1 of 26.9 kDa compared to a calculated value of 
21.7 kDa, with an offset of 0.05 (Fig. 2.6B).  This indicates an equilibrium favoring 
monomers with the ability to form dimers for a small percentage of molecules.  The 
molecular weight from AUC for apo-CIB1 was 23.6 kDa, with an offset of -0.021, indicating 
a population almost entirely monomeric.  To determine whether Ca2+-CIB1 forms dimers in 
the presence of ligand, we performed experiments with equivalent concentrations of αIIb 
peptide in the sample and reference cells.  The molecular weight determined from AUC was 
25.5 kDa (offset of -0.255), as compared to a calculated molecular weight for a 1:1 
CIB1/peptide complex of 24.8 kDa, indicating the prevalence of a 1:1 complex of CIB1 and 
αIIb.  The high offset values obtained for experiments with αIIb are indicative of the difficulty 
in precisely matching the αIIb concentration in the reference and sample cells. 
 2.3.5 Potential Ligand Binding Site of CIB1 
 EF-hand-containing proteins contain hydrophobic pockets that bind the amphipathic 
α-helices of their ligands.  These binding pockets exist on the opposite side of the molecule 
from the Ca2+-binding sites of EF-hands 3 and 4.  In Figure 2.7, the molecular surface of 
CIB1, KChIP1, and calcineurin B are colored by hydrophobic potential, and the positions of 
the portions of calcineurin A and Kv4.2 bound in calcineurin B and KChIP1, respectively, 
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Fig. 2.7.  CIB1 contains a strongly hydrophobic channel that is preserved in other 
EF-hand-containing proteins.  CIB1, KChIP1, and calcineurin B were read by the 
program SYBYL version 6.9.1 (www.tripos.com), hydrogens were added, and 
MOLCAD molecular surfaces were generated and colored to represent the spectrum of 
hydrophobic potential (red, highly hydrophobic; blue, highly hydrophilic).  The 
orientation of CIB1 in this molecular surface representation is very similar to that in 
Fig. 2.1.  The region of calcineurin A in contact with calcineurin B, as well as the Kv4.2 
peptide, are shown as helical worms in the binding sites of calcineurin B and KChIP1, 
respectively, and their boundaries are enumerated.  Positions of the C-terminal H10 
helices of CIB1, calcineurin B, and KChIP1 on these surfaces are labeled, as are 
selected secondary structural elements.
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are traced.  Residues within the hydrophobic binding pocket of CIB1 are denoted in the 
sequence alignment on Fig. 2.4. 
 In the case of calcineurin B, calcineurin A binds in a hydrophobic channel formed 
from residues in helices H1, H2, H3, H7 (equivalent to H1, H3, H4 and H8 in CIB1) and the 
C-terminal region (Fig. 2.7)(Griffith et al., 1995).  In KChIP1, the Kv4.2 peptide binds as a 
continuation of the C-terminal helix H10 in a hydrophobic channel formed by EF1 and EF2 
(Zhou et al., 2004).  Similarly-placed hydrophobic channels have been found in other NCS 
proteins (Ames et al., 1999;Bourne et al., 2001;Vijay-Kumar, Kumar, 1999) . 
 CIB1 contains a hydrophobic channel just following the C-terminus of the molecule, 
as in KChIP1, but the binding pocket is considerably narrower than that of KChIP1.  This is 
in part due to the bend at Pro 61 and the associated position of helix H3b, which pushes 
further into the hydrophobic binding pocket relative to the similar helix in KChIP1.  Binding 
studies have shown that CIB1 binds to a minimal 15-amino acid region of integrin αIIb (Barry 
et al., 2002), which corresponds to four alpha-helical turns.  The hydrophobic channel (~18 Å 
across) of CIB1 would be too small to bind four turns of an α-helix (> 25 Å).  However, this 
hydrophobic channel continues, albeit in a narrower form, on either side of the H10 helix. 
2.4 Discussion 
 2.4.1   The CIB1 family is distinct from the CnB and NCS families 
 The x-ray crystallography structure shows that like its homologs, CIB1 contains four 
EF-hands, with EF3 and EF4 binding Ca2+.  EF1 is highly degenerate with an additional eight 
residues in its loop region.  These additional residues are not found in CnB and the NCS 
proteins, although NCS proteins also do not bind Ca2+ in this EF-hand due to a conserved 
Cys-Pro sequence. 
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 As predicted, CIB1 has high structural homology to CnB and NCS proteins.  Unlike 
CaM, these proteins do not contain a flexible linker between the N and C lobes.  Instead, 
there is a large interface between the N and C lobes.  CIB1 contains a hydrophobic binding 
pocket in the same location as that of its homologs.  With the aim of learning more about the 
placement of CIB1 with respect to the CnB and NCS proteins, we performed additional 
biochemical analysis.  CIB1 displays many differences from the NCS family, including 
ubiquitous cellular distribution.  In addition, CIB1 does not appear to dimerize.  CIB1 lacks 
conserved residues within the NCS family and is less homologous to NCS proteins than they 
are to one another.  Upon sequence analysis, it became clear that CIB1 and its homologs 
form a family of proteins distinct from the CnB and NCS proteins.  CIB1 homologs are 
widespread in the animal kingdom, with CIB1 homologs found in animals as simple as 
arthropods. 
 2.4.2  Differences between our structure and a new Ca2+-CIB1 structure 
 After publication of our Ca2+-CIB1 x-ray crystal structure (PDB code 1XO5), data 
showing an additional x-ray crystal structure (PDB code 1Y1A) was published (Blamey et 
al., 2005).  The most striking difference between the two structures is that 1Y1A crystallizes 
as a head-to-tail dimer.  While this dimerization was mediated by hydrophobic interactions, 
an additional study reported that CIB1 dimerization is mediated by covalent bonds (Sobczak 
et al., 2005).  Dimers were seen in AUC and gel filtration and were dissociated into 
monomers after incubation with a reducing agent for 72 hours.  The gel filtration experiments 
in section 2.3.4 were performed under reducing conditions, which resulted in only 
monomeric species being observed.  However, the AUC experiments in section 2.3.4 were 
performed under non-reducing conditions.  The difference in results between the AUC 
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AB	 	 	 	
C	 	 	 	
1Y1A	 	 	      1XO5
N
N
N
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C
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Fig. 2.8.  Comparison of the x-ray crystal structures of Ca2+-CIB1, PDB code 1Y1A 
and 1XO5.  (A) Superposition of the N lobe of 1Y1A (blue) and 1XO5 (green) shows a 
difference in the orientation of the C lobe.  (B) N lobes of each structure showing 
differences in the N-terminal extensions of 1Y1A (residues 9-23 colored blue) and 1XO5 
(residues 12-23 colored green).  (C) C lobes of each structure showing differences in the C-
terminal extension (residues 180-191) colored as in (A) and (B).  Termini are labeled and 
Ca2+ ions are shown as black spheres.  Adapted from Yamniuk et al., 2006, with permission 
from the American Society for Biochemistry and Molecular Biology.
63
experiments in section 2.3.4 and those performed by Sobczak et al. is not apparent.  
Dimerization was not seen in non-reducing SDS-PAGE of cell extracts (Sobczak et al., 
2005), so it appears that dimers are not found in vivo.  The dimer seen in the 1Y1A structure 
of Blamey et al. could be an artifact of crystallization. 
 The 1Y1A structure has a different orientation between the N lobe (comprised of EF1 
and EF2) and C lobe (comprised of EF3 and EF4) compared to 1XO5 (our CIB1 structure), 
although each lobe is very similar when analyzed separately (Fig. 2.8A).  Residue positions 
determined by heteronuclear single quantum correlation (HSQC) have been determined for 
88% the backbone atoms of CIB1 (Yamniuk et al., 2006).  Residual dipolar coupling (RDC) 
reveals a better correlation to 1XO5 than 1Y1A.  However, when the N and C lobes of the 
two crystal structures were analyzed independent of one another with the NMR data, each 
lobe of 1XO5 and 1Y1A strongly correlated with the NMR data.  These data suggest that the 
N and C lobes are likely to be oriented as seen in 1XO5.  In addition, the N and C lobe 
appear to have a fixed orientation in solution based on nuclear overhauser effect (NOE) 
experiments.  This lack of flexibility is shared with NCS and CnB family proteins and is in 
contrast to the flexibility seen in CaM. 
 Another difference between 1Y1A and 1XO5 is the orientation and helical nature of 
the N-terminus.  Both studies used CIB1∆1-8 for crystallization.  The N-terminus of 1Y1A is 
an α-helix from residue 9-20.  The N-terminus of 1XO5 had poor electron density for 
residues 8-11 and only a half turn of an α-helix residues 14-16.  Data obtained from NMR 
shows a stronger correlation with 1Y1A in this region (Yamniuk et al., 2006), indicating this 
is the more likely position of the N-terminus.  Correlating the C-terminal helices of the 
crystal structures with NMR data was not possible due to low signal intensity in this region. 
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 2.4.3 Interaction of αIIb with the hydrophobic binding pocket of CIB1 
 As described in section 2.3.5, the hydrophobic binding pocket of CIB1, as described 
in the structure of CIB1 alone, is too small to interact with the four α-helical turns of αIIb that 
CIB1 is expected to bind.  A model whereby the H10 helix is displaced upon αIIb binding 
would effectively increase the size of the hydrophobic binding pocket.  Displacement of the 
H10 helix would reveal more hydrophobic residues, thereby increasing the size of the 
hydrophobic binding pocket and allowing the entire minimal αIIb-binding sequence to bind.  
Displacement of the C-terminus is also suggested by the structure of the Arabidopsis EF-
hand-containing protein AtCBL2 (Nagae et al., 2003).  In the structure of AtCBL2, the C-
terminus completely covers the hydrophobic binding groove, and consequently it has been 
suggested that upon ligand binding the C-terminus is released from this groove. 
 A recent study suggests that the H10 helix of CIB1 is indeed displaced by αIIb binding 
(Yamniuk et al., 2006).  Preliminary analysis of NMR spectra of Ca2+-CIB1 in the presence 
of αIIb indicated a high degree of flexibility in the H10 helix.  The signal for much of the H10 
helix became broadened beyond detection, suggestive of conformational changes in the 
intermediate NMR timescale.  In addition, the signal for residues 189-191 greatly increased 
and showed very small nuclear overhauser effect (NOE) values, which indicates a high 
degree of conformational flexibility. 
 Residues of CIB1 most affected by αIIb binding were identified by chemical shift 
perturbation (CSP)(Fig. 2.9)(Yamniuk et al., 2006).  As predicted, the residues most affected 
by αIIb binding were located within the hydrophobic channel.  While there were some 
changes in the N lobe of the molecule, the largest CSP values were found in the C lobe of the 
protein, especially on the hydrophobic faces of H6 and H7 (EF-3), H8 and H9 (EF-4), and 
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Fig. 2.9.  Identification of the αIIb binding site on CIB1 by chemical shift perturbation 
(CSP).  (A) Induction of CSP by αIIb binding to CIB1 plotted by amino acid residue.  CSP 
for HN and N are shown as open bars and CSP for Cα and Cβ are shown as solid bars.  
Secondary structure on the top part of the panel is shown as boxes and arrows representing 
α-helices and β-sheets, respectively.  Residues unable to be analyzed are shown as solid 
circles.  (B) Worm diagram of CIB1 with residues showing high CSP values shown in red.  
The H10 helix is colored green, and the Ca2+ ions are grey spheres.  (C) Space filling 
representation of CIB1 colored as in (B).  Residue R33, which is thought to form a salt 
bridge with αIIb, is highlighted.  Adapted from Yamniuk et al., 2006, with permission from 
the American Society for Biochemistry and Molecular Biology.
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H10 (C-terminus).  Some hydrophobic residues showing large CSP values, including three 
residues (Phe 115, Leu 131, and Phe 173) previously found to affect αIIb binding without 
affecting the CIB1 structure (as measured by circular dichroism)(Barry et al., 2002), are 
located underneath the H10 helix (Fig. 2.9B,C), suggesting that these residues might be part 
of the binding interface with αIIb.  These data indicate that the binding pocket of CIB1 bound 
to αIIb is similar to that of CnB bound to CnA, with a possible location of the H10 helix of 
CIB1 being next to the bound αIIb α-helix.  The H10 helix is not required for binding αIIb, 
since a CIB1 mutant lacking the H10 helix (CIB1∆H10) bound αIIb with a similar affinity to 
WT CIB1 (Yamniuk et al., 2006). 
 Additional data suggests that the H10 helix only weakly associates with CIB1 and 
prevents nonspecific binding (Yamniuk et al., 2006).  Steady-state fluorescence spectroscopy 
with the hydrophobic probe 8-anilino-1 naphalenesulfonate showed that CIB1∆H10 has a 
significantly larger hydrophobic surface than wild-type CIB1.  This mutant had a tendency to 
self-aggregate and only weakly bound an H10 helix peptide as measured by isothermal 
titration calorimetry (ITC).  The CIB1∆H10 mutant, but not WT CIB1, showed a weak 
interaction with a peptide derived from smooth muscle myosin light chain kinase 
(smMLCK).  These data suggest that the H10 helix confers binding specificity by preventing 
self-association and non-specific binding to targets.  Taken together with the CSP data, it 
appears that the weakly associated H10 helix is displaced in the high-affinity interaction with 
αIIb. 
 Although the majority of the binding interface with αIIb appears to be located on the C 
lobe of CIB1 (Yamniuk et al., 2006), the N lobe also participates in the interaction.  Residues 
within the N lobe, including the R33 residue that is thought to form a salt bridge with the 
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acidic C-terminus of αIIb, also undergoes changes in CSP values upon αIIb binding.  In 
addition, the C lobe alone cannot bind αIIb by ITC.  In fact, NMR experiments showed that 
the C lobe adopts a different conformation when the N lobe is not present.  These 
experiments suggest that while the majority of the binding interface is located within the C 
lobe, the N and C lobes are both necessary for binding αIIb.  The N and C lobes of CnB both 
interact with CnA, although only the isolated C lobe, but not the isolated N lobe, can activate 
CnA (Jiang, Wei, 2003).  Both recoverin and KChIP1 interact with ligand via their N lobes 
(Ames et al., 2006;Zhou et al., 2004).  Therefore, the exact location of the binding interface 
of EF-hand-containing proteins is varied. 
 The unique flexible linker between the N and C lobes of CaM allows it to utilize a 
variety of binding interfaces specific to different ligands (Hoeflich, Ikura, 2002).  However, 
the N and C lobes of other CIB1 homologs, such as CnB and NCS proteins, have a fixed 
orientation in solution and present one binding site to ligands (Ames et al., 2006;Zhou et al., 
2004).  The N and C lobes of CIB1 also seem to be in a fixed orientation, since residues 
located between these lobes have NOE values indicative of low flexibility (Yamniuk et al., 
2006).  Because of this rigid structure, CIB1 likely has fewer binding sites than CaM.  This 
diversity of binding mechanisms of CaM, and lack thereof for CIB1 homologs, reflects the 
sheer number of cellular events that involve CaM.  Data indicates that CIB1 does contain a 
binding site other than the hydrophobic binding pocket, since CIB1 residues outside this 
pocket are critical for co-immunoprecipitating CIB1 with PDK1 (Zhao et al., 2007).  
Additional study will verify the importance of these binding residues.   
 In conclusion, the crystal structure of CIB1 reveals significant structural similarity to 
other EF-hand containing proteins and confirms that only EF-hands 3 and 4 bind Ca2+ 
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through canonical interactions characteristic of EF-hand domains.  The major differences 
between CIB1 and the NCS and calcineurin B families are in the overall structure of EF1 and 
within the N-terminal portions.  CIB1 contains a hydrophobic binding pocket conserved in its 
homologs, and binding of αIIb and other targets is likely to displace the C-terminal helix from 
this binding pocket.  A family of proteins related to CIB1 has been discovered that is distinct 
from its closest homologs, calcineurin B and the NCS protein family.  Future structural 
studies of CIB1 and CIB family members with high-affinity binding peptides from target 
proteins such as integrin αIIb, in combination with further biochemical and cellular assays, 
will extend our understanding of the role of this family of proteins in cellular signaling. 
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CHAPTER III - BINDING OF CIB1 TO ADDITIONAL α INTEGRINS 
 
 
 
 
 
 
 
 
 
 
 
3.1    Introduction 
 CIB1 was originally discovered in a yeast two-hybrid screen to identify binding 
partners of the αIIb integrin subunit.  The αIIbβ3 integrin is a platelet-specific receptor for 
extracellular matrix proteins such as fibrinogen and von Willebrand factor.  Upon injury to 
the blood vessel wall, platelet aggregation at the site of injury is mediated by fibrinogen 
crosslinking via αIIbβ3. 
 A direct, high-affinity (0.7 µM) interaction between CIB1 and αIIb was established by 
ITC (Shock et al., 1999).  CIB1 coimmunoprecipitates with αIIb in agonist-stimulated 
megakaryocytes (Yuan et al., 2006b).  In addition, CIB1 overexpression inhibits agonist-
induced fibrinogen binding in megakaryocytes.  In the converse experiment, megakaryocytes 
treated with CIB1 siRNA show increased agonist-induced fibrinogen binding.  CIB1 appears 
not to cause integrin tail separation, consistent with data showing it does not activate αIIbβ3.  
In preliminary NMR studies, β3 can still interact with αIIb when CIB1 is present (Jun Qin, 
unpublished data).  In contrast, talin binding to αIIbβ3 causes integrin cytoplasmic tail 
separation and integrin activation (Vinogradova et al., 2002).  Talin is known to bind integrin 
β tails and binds αIIb in solid-phase binding studies (Knezevic et al., 1996;Yuan et al., 
2006b), and talin and CIB1 compete for binding to αIIb alone and αIIbβ3 (Yuan et al., 2006b).  
It is possible that CIB1 prevents αIIbβ3 activation by inhibiting binding of talin to αIIb. 
 During initial yeast two-hybrid experiments showing binding of CIB1 to αIIb, 
additional integrin cytoplasmic tails (αV, α2, α5, β1, and β3) were tested for binding.  None of 
these integrins exhibited binding by yeast two-hybrid analysis.  The sequences used for these 
experiments are shown in Fig. 1.5.  Subsequent to performing these experiments, newer 
binding data have shown that the minimal CIB1 binding sequence on αIIb is 
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983LVLAMWKVGFFKRNR997 (Barry et al., 2002).  This sequence spans part of the 
putative transmembrane region of αIIb, since the cytoplasmic region is not predicted to begin 
until K989 (Fig. 1.4).  The α2 sequence used in yeast-two hybrid for determining CIB1 
binding partners lacked this essential transmembrane region.  In addition, L983 of αIIb was 
found to be necessary for binding CIB1 (Barry et al., 2002), and the α5 and αV sequences 
used in yeast-two hybrid lacked this hydrophobic residue.  In a separate study, deletion of 
983LVL preventing binding of CIB1 to αIIb by ITC (Shock et al., 1999). 
 Recent NMR data shows that CIB1 interacts with α5 (Jun Qin, unpublished data).  In 
addition, overexpressed CIB1 inhibits α5-mediated migration in HeLa cells, rat embryo 
fibroblast (REF52), and NIH3T3 cells (Leisner et al., 2005).  Therefore, we decided to re-
examine whether CIB1 binds α integrins other than αIIb. 
 The CIB1 null mouse has abnormalities that are most likely not caused by its effect 
on αIIbβ3.  In fact, αIIbβ3 expression and activity, as well as bleeding times, are normal (Jan 
DeNofrio, unpublished data).  However, the male null mouse is sterile due to a 
spermatogenesis defect (Yuan et al., 2006a).  In addition, the CIB1 null mice have a defect in 
ischemia-induced angiogenesis (Zayed et al., 2007).  Primary mouse endothelial cells taken 
from the knockout mouse show decreased migration and proliferation.  By determining 
whether CIB1 binds α integrins other than αIIb, we can start to assess the reason for the 
knockout mouse phenotype. 
3.2 Materials and Methods 
 Protein purification and peptide synthesis − Full-length CIB1 was purified as 
described in Specific Aim I.  Peptides were synthesized by an in-house facility and purified 
by high pressure liquid chromatography (HPLC).  Peptide mass was confirmed by MALDI 
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MS/MS on a 4700 Proteomics Analyzer (Applied Biosystems).  Sequences used were αIIb 
(Ac-LVLAMWKVGFFKRNRPPLEEDDEEGQ), αIIb trunc (Ac-LVLAMWKVGFFKRNR), 
α2 (LVAILWKLGRRKRKYEKMTKNPDEIDETTELSS), α4 (ISYVMWKAGFFKRQY), 
α5 (LIYILYKLGFFKRSLPYGTAMEKAQLKPPATSDA), αL (Ac-
IFIVLYKVGFFKRNLKEKMEAGR), and αM (ITAALYKLGFFKRQY).  The αV peptide 
(LVFVMYRMGFFKRVRPPQEEQERE) was insoluble. 
 Isothermal titration calorimetry − Full-length CIB1 was purified as stated in 
section 2.2, and gel filtration fractions were pooled, concentrated, and frozen in 100 mM 
HEPES, 150 mM NaCl (pH 7.5).  Before ITC experiments, CaCl2 was added to CIB1 at a 
final concentration of 10 mM.  Peptides made fresh were dissolved in 100 mM HEPES, 150 
mM NaCl, 10 mM CaCl2 (pH 7.5), with the exception of α4, where the entire experiment was 
performed at 20 µM CaCl2.  Concentrations verified by absorbance readings at 280 nm were 
between 1.1 and 2.2 mM for CIB1 and 15 and 45 µM for peptides.  Experiments with each α 
integrin peptide were performed at least twice on a MicroCal VP-ITC microcalorimeter.  
Samples were degassed 10-15 min.  Injections of 5 µl CIB1 were added at 240 s intervals at 
25°C.  The heats of dilution were estimated from injections at timepoints after saturation had 
occurred.  These values were subtracted from the data before one-site curve fitting was 
performed using Microcal, LLD Origin 7.  The stoichiometry (N), association constant (Ka), 
and enthalpy change (∆H) were obtained directly from the data, and the Gibbs free energy 
change (∆G) and entropy change (∆S) were calculated by Equations 1 and 2: 
∆G = -RTlnKa      (1) 
∆G = ∆H − T∆S   (2) 
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The stoichiometry for α2, α4, αL, and αM was fixed at 1 in order to avoid the possibility of 
multiple minima when deconvoluting the data (Wiseman et al., 1989).  When N, Ka, and ∆H 
are floated simultaneously, variable results can arise from multiple minima. 
3.3 Results 
 Sequences of α integrin cytoplasmic tail peptides used for ITC are shown in Fig. 3.1.  
Truncated αIIb (αIIb trunc) showed the same thermodynamic parameters as full-length αIIb, so 
truncated α integrin peptides were used in subsequent experiments.  Truncated versions of 
α2, α5, and αL were not soluble, so longer peptides were synthesized and determined to be 
soluble.  The α4 peptide was not soluble when the ITC buffer contained 10 mM CaCl2 but 
was soluble when the CaCl2 concentration was reduced to 20 µM. 
 Binding of αIIb to CIB1 showed thermodynamic parameters, including binding that is 
driven by enthalpy, very similar to those seen previously by ITC (Fig. 3.3)(Shock et al., 
1999;Yamniuk, Vogel, 2005).  The affinity (1.8 µM) was lower than that seen in previous 
ITC studies {0.6 µM (Yamniuk, Vogel, 2005) and 0.7 µM (Shock et al., 1999)} and intrinsic 
tryptophan fluorescence studies {0.3 µM (Barry et al., 2002)}, which can be accounted for by 
differences in methods of determining protein and peptide concentrations. 
 In addition to binding αIIb, CIB1 also bound α2, α4, α5, αL, and αM (Fig. 3.2).  All 
were high affinity interactions, with αM being of the lowest affinity at 23.6 µM (Table 3.1).  
Surprisingly, binding of CIB1 to these additional α integrin peptides was driven by entropy 
and not enthalpy as seen with αIIb.  This is likely due to α integrin peptide oligomerization.  
Integrin subunits are known to homooligomerize (Li et al., 2004;Schneider, Engelman, 
2004).  Breaking α integrin homomeric interactions would require heat, thereby explaining 
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LVLAMWKVGFFKRNRPPLEEDDEEGQ
LVLAMWKVGFFKRNR
LVAILWKLGFFKRKYEKMTKNPDEIDETTELSS
ISYVMWKAGFFKRQY
LIYILYKLGFFKRSLPYGTAMEKAQLKPPATSDA
IFIVLYKVGFFKRNLKEKMEAGR
ITAALYKLGFFKRQY
         αIIb
αIIb trunc
            α2
            α4
            α5
            αL
           αM
Integrin                Sequence
Fig. 3.1.  Sequences of α integrin peptides used for isothermal titration calorimetry.  
Residues that are hydrophobic are colored red, acidic are blue, and basic are green. 
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Integrin
aIIb
aIIb trunc
a2
a4
a5
aL
aM
N
1.1 ± 0.0
1.1 ± 0.0
1.0 ± 0.0
1.0 ± 0.0
0.9 ± 0.0
1.0 ± 0.0
1.0 ± 0.0
DH (kJ/mol)
-17.1 ± 0.1
-17.3 ± 0.1
2.4 ± 0.1
1.8 ± 0.0
21.4 ± 0.3
8.2 ± 0.4
8.8 ± 0.2
Kd (mM)
1.8 ± 0.1
1.9 ± 0.1
3.9 ± 0.4
7.9 ± 0.6
6.9 ± 0.4
3.2 ± 0.6
23.6 ± 1.4
TDS (kJ/mol)
15.7
15.5
33.2
30.9
50.7
39.5
35.2
DG (kJ/mol)
-32.8
-32.8
-30.8
-29.1
-29.3
-31.3
-26.4
Table 3.1.  Thermodynamics of CIB1 binding to α integrin cytoplasmic tail peptides as 
determined by isothermal titration calorimetry. 
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the endothermic nature of the reaction. 
3.4 Discussion 
 Solubility was a problem with the truncated versions of α2, α5, and αL, so longer 
sequences were used for these integrin peptides.  However, a longer sequence was not 
sufficient to solubilize αV.  Therefore, a maltose-binding protein (MBP) fusion construct of 
αV will be used in future experiments.  Preliminary experiments with MBP- αIIb show 
appropriate binding to CIB1 by ITC. 
 Comparable affinities to those obtained from ITC were obtained in single 
experiments using a fluorescent label on CIB1 (Yi Wu, unpublished data).  Affinities were 
determined to be 0.3 µM for αIIb, 0.9 µM for α2, 7.8 µM for α4, 1.9 µM for α5, and 77.6 µM 
for αL.  A Kd was not able to be obtained for αM by fluorescence.  We were unable to repeat 
these experiments due to solubility problems with the fluorescent probe, so we believe the 
ITC data is more reliable since it has been repeated several times.  The differences in Kd 
values between ITC and fluorescence experiments are probably a result of technical issues 
arising from fluorescent probe insolubility or differences in experimental methods in 
determining protein concentrations. 
 In contrast to the αIIb/CIB1 reaction that was driven by enthalpy, the reaction with all 
other α integrins tested was driven by entropy.  The reason for this is likely to be a result of 
oligomerization of the additional α integrin peptides.  A simple way to test for α integrin 
peptide oligomerization is to perform AUC.  Another way to test for this is to perform ITC 
experiments where the α integrin peptide is titrated into buffer.  If dissociation of oligomers 
occurs upon titration, thermodynamic parameters for the reaction can be determined (Luke et 
al., 2005). 
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 The CIB1 null mouse has normal bleeding times and αIIbβ3 activation.  However, 
there are other aberrations in its phenotype.  The male CIB1 null mouse is sterile due to a 
spermatogenesis defect (Yuan et al., 2006a).  The CIB1 null mouse has increased plasma P-
selectin and von Willebrand factor (Jan DeNofrio, unpublished data). Both genders display 
an angiogenesis defect (Mohamed Zayed, manuscript in submission).  There is decreased 
endothelial cell function, proliferation, and integrin-mediated migration.  Endothelial cells 
express α5β1 and αVβ1, and the absence of CIB1 in these cells could be causing integrin 
dysregulation directly by not binding to integrin tails, or indirectly by not binding other target 
proteins.  It is known that CIB1 inhibits α5-mediated migration in REF52 and HeLa cells 
through the PAK1/LIMK/cofilin pathway (Leisner et al., 2005).  In CHO cells, CIB1 
increased α5-mediated migration (Naik, Naik, 2003a).  The different effects of CIB1 on 
migration could be caused by different signaling pathways predominating in different cell 
types. 
 The quantity of CIB1 in cell types other than platelets is unknown.  In platelets, the 
quantity of CIB1 (~5,000 copies) per platelet is low compared to that of talin and αIIbβ3 
(80,000 copies).  The low quantity of CIB1 in platelets might explain the lack of a platelet 
phenotype in the CIB1 null mice.  In cell types with higher quantities of CIB1, it is possible 
that CIB1 has a large effect on integrin function.  If CIB1 acts on other α integrins similarly 
to how it acts on αIIb, it might lock the α and β integrin tails together in an inactive state.  
This has profound implications for potential therapeutics.  A small molecule targeting the 
CIB1/integrin interaction or mimicking CIB1 could inhibit pathological integrin activation. 
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CHAPTER IV - CONCLUSIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 In this work, we have determined the x-ray crystal structure of CIB1 to 2.0 Å.  The 
structure revealed a high degree of structural homology to CnB and the NCS proteins.  Like 
its homologs, CIB1 contains four EF-hands, two of which bind Ca2+.  EF1 and EF2 do not 
bind Ca2+ due to insertions in the Ca2+-binding loop and a lack of critical acidic residues that 
coordinate Ca2+.  Measurement of the angle between the E and F helices of EF2, EF3, and 
EF4 showed similar angles for each EF-hand, suggesting that Ca2+-free EF2 adopts an open 
conformation typical of Ca2+-bound EF-hands. 
 CIB1 contains a hydrophobic binding pocket in the same location as that of its 
homologs.  The C-terminal H10 helix interacts with this pocket.  In the case of KChIP1, 
binding of ligand occurs as an extension of the H10 helix, with all of the binding residues in 
the N lobe (Fig. 2.6).  The binding of rhodopsin kinase to recoverin shows a binding pocket 
also entirely within the N lobe (Ames et al., 2006).  In the structure of CnB, CnA binds along 
the entire length of CnB and the H10 helix is located next to the CnA helix (Fig. 2.7).  The 
structure of CnB in the absence of ligand has not been solved, so it is not known whether the 
H10 helix is displaced by CnA binding or if it is always located in this position.  The H10 
helix of CIB1 is located in a similar position to that of KChIP1, although data suggests it is 
displaced upon ligand binding.  Data from NMR experiments show that the H10 helix of 
CIB1 is highly flexible, and residues implicated in αIIb binding by NMR (Yamniuk et al., 
2006) and mutational analysis (Barry et al., 2002) are located underneath the H10 helix (Fig. 
2.9).  In addition, the H10 helix only weakly binds CIB1 and acts to decrease nonspecific 
binding (Yamniuk et al., 2006).  Based on these data, it is likely that the H10 helix is 
displaced by ligand binding, and its displaced location might be similar to that of CnB. 
 Whether CIB1 oligomerizes was tested by gel filtration and analytical 
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ultracentrifugation.  In the presence or absence of Ca2+ and ligand, CIB1 existed as 
monomers.  This is in contrast to the NCS proteins, which often oligomerize in the presence 
or absence of Ca2+ and ligand.  CIB1 is more similar to monomeric CnB in this respect. 
 In order to more fully understand the place of CIB1 with respect to its homologs, we 
performed sequence analysis of CIB1 and the CnB and NCS families.  Based on dendrogram 
analysis, we found that CIB1 forms a unique family distinct from the CnB and NCS families.  
We identified three human CIB1 homologs in the sequence database: CIB2, CIB3, and CIB4.  
The mRNA from these genes was found in the CIB1-/- mouse (Jan DeNofrio, unpublished 
data).  Further study will determine whether these homologs are expressed as proteins.  
Indeed, these homologs might be compensating for the loss of CIB1 in the CIB1-/- mouse.  
Antibodies were developed for CIB2 (Carlos Rosales, unpublished data) and will be 
developed for CIB3 and CIB4.  We will test whether these homologs show increased 
expression in the CIB1-/- mouse compared to WT mice.  The CIB2 protein, which is 37% 
identical to CIB1, does not bind αIIb in yeast two-hybrid studies (David Shock, unpublished 
data).  The closest sequence homolog of CIB1, CIB4 (44% identity), has not been tested for 
integrin binding.  Expression and determination of binding partners will be studied for each 
CIB1 homolog. 
 Myristoylation is a regulatory mechanism for many small EF-hand-containing 
proteins.  One function of the myristoyl group is to localize these proteins to the membranes.  
However, myristoylation is not always required for localization to membranes, as 
unmyristoylated CnB still displays some localization to membranes (Kennedy et al., 
1996c;Zhu et al., 1995).  The importance of myristoylation in CIB1 localization to 
membranes has not been fully explored.  CIB1 shows increased membrane localization in 
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platelets upon treatment with agonist (Naik, Naik, 2003b;Shock et al., 1999;Yuan et al., 
2006b) and in REF52 (Leisner et al., 2005), CHO, HUVEC, and NIH3T3 cells (Naik, Naik, 
2003a) plated on fibronectin.  A CIB1 G2A mutant that cannot be myristoylated displayed a 
similar subcellular localization as myristoylated CIB1 in HeLa cells, and neither construct 
showed a high degree of membrane localization (Zhu et al., 2004).  However, the lack of 
membrane localization in these experiments might have been due to the absence of agonist, 
including extracellular matrix protein ligands.  Conclusive data for the requirement of CIB1 
myristoylation in localizing to membranes has not been shown. 
 In addition its role in membrane localization, the Ca2+-myristoyl switch of recoverin 
regulates its interaction with rhodopsin kinase. Binding of Ca2+ is required to extrude the 
myristoyl group from the ligand binding pocket of recoverin (Ames et al., 2006).  In addition, 
the presence of the myristoyl group on recoverin is necessary for Ca2+ binding to EF2 and 
EF3 to be cooperative (Ames et al., 1995).  Myristoylated recoverin has a lower affinity for 
Ca2+, with a dissociation constant of 17 µM as opposed to 0.11 µM and 6.9 µM for the EF-
hands of unmyristoylated recoverin (Ames et al., 1995). 
 For Ca2+ and ligand binding to be affected by myristyolation, CIB1 would probably 
need to have a Ca2+- myristoyl switch.  It does not appear to contain a Ca2+-myristoyl switch, 
since treatment of Cos-7 cells with ionomycin, a Ca2+ ionophore, does not cause membrane 
localization of CIB1 (Blazejczyk et al., 2006).  However, these experiments were performed 
with immunofluorescence microscopy and not confocal microscopy, and only one cell was 
shown, so conclusive data has yet to be provided.  Whether CIB1 contains a Ca2+-myristoyl 
switch can be determined by confocal microscopy and subcellular fractionation with 
ionomycin treatment.  If it does contain a Ca2+-myristoyl switch, the myristoyl group would 
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interact with residues of Ca2+-free CIB1.  The Ca2+-myristoyl switch would be expected to 
affect Ca2+ cooperativity and ligand binding.  If CIB1 is shown definitely to lack a Ca2+-
myristoyl switch, its myristoylation would not be expected to affect its binding to ligands or 
Ca2+. 
 It is known that CIB1 inhibits agonist-induced αIIbβ3 activation in megakaryocytes 
(Yuan et al., 2006b), so CIB1/integrin interactions are of much interest.  Structural analysis 
of CIB1 with αIIb is being performed by our collaborator, Jun Qin.  Preliminary NMR 
analysis shows that β3 is able to bind αIIb in the presence of CIB1.  This is in contrast to talin, 
which causes α and β tail separation and integrin activation upon binding to β3.  In addition 
to binding β subunits, talin binds αIIb (Leisner et al., 1999;Yuan et al., 2006b), and CIB1 and 
talin compete for binding to αIIb in ELISA assays (Yuan et al., 2006b).  Therefore, CIB1 
binding to αIIb could be preventing integrin tail separation by blocking talin from binding 
αIIb.  Determining the structure of the αIIb cytoplasmic tail peptide bound to CIB1 will 
increase our understanding of the mechanism by which CIB1 inhibits αIIbβ3. 
 We found that in addition to binding αIIb, CIB1 binds several additional α integrin 
cytoplasmic tails, including α2, α4, α5, αL, and αM.  The absence of binding observed in 
previous yeast two-hybrid data is most likely a result of α integrin constructs that lacked 
critical CIB1-binding residues.  We characterized the thermodynamic parameters for CIB1 
binding to these additional α integrins, and micromolar affinities were seen for each, with the 
lowest affinity being 23.6 µM for αM.  The αV integrin was unable to be tested because it was 
insoluble, but future experiments with an MBP-αV fusion construct will determine whether 
binding occurs. 
84
 Interestingly, CIB1 bound to all α integrins tested.  It is possible that CIB1, like talin, 
is not specific to a particular class of integrins.  It has been hypothesized that talin is required 
for integrin activation (Tadokoro et al., 2003).  However, several pieces of data suggest that 
talin is not required for activation of all integrins (Arnaout et al., 2005).  Differences in 
integrin binding affinities and cell types might drive these differences. 
 To understand the importance of our in vitro binding assays, we will perform co-
immunoprecipitation experiments to determine whether CIB1 binds these other α integrin in 
cell lysates.  Preliminary studies are being performed to determine whether endogenous α 
integrins co-immunoprecipitate with CIB1.  These experiments will be performed with all α 
integrins that exhibited binding in section 3.3.  Since α2β1 is found on platelets, isolated 
human platelets can be used for these co-immunoprecipitation experiments.  Endogenous 
CIB1 and αIIbβ3 have been successfully co-immunoprecipitated from human platelets (Yuan 
et al., 2006b).  A greater amount of CIB1 co-immunoprecipitates with αIIb upon agonist 
stimulation (Naik, Naik, 2003b;Yuan et al., 2006b), so agonists should be used for co-
immunoprecipitation studies with other α integrins.  HEK293 and mouse NIH3T3 cells have 
large amounts of α5β1, αV, and CIB1, so they would be appropriate for performing co-
immunoprecipitations with these α integrins.  Co-immunoprecipitation of CIB1 with α4β1, 
αLβ2, and αMβ2 can be performed with human white cell isolates or white cell lines such as 
Jurkat T cells. 
 To determine whether CIB1 affects the function of integrins other than αIIbβ3, we will 
overexpress and knockdown CIB1 in appropriate cell types.  To assess integrin activation 
states, we will perform flow cytometry with fluorescently-labeled ligands or antibodies 
specific for activated integrins.  To analyze whether CIB1 affects migration mediated by 
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different integrins, we will perform Boyden chamber migration experiments. 
 An important tool for determining the effect of CIB1 on integrin activation is CIB1 
null cells.  Our lab has already successfully cultured primary CIB1 null mouse lung 
endothelial cells (MLECs) and mouse heart endothelial cells (MHECs).  Primary cultures 
from wild-type mice are used as a control.  Migration of CIB1 null MLECs is decreased 
compared to wild-type on fibronectin in unstimulated and growth factor-stimulated settings 
(Zayed et al., 2007).  The fibronectin receptors in endothelial cells are α5β1 and αVβ1.  To 
determine which integrin mediates this migration, cells can be incubated with function-
blocking antibodies to each of the integrins.  For example, a function-blocking antibody to 
α5β1 would be expected to decrease migration mediated by α5β1.  A function-blocking 
antibody to α5β1 inhibits CIB1-induced migration in CHO cells (Naik, Naik, 2003a).  An 
alternative to using CIB1 null endothelial cells is to perform overexpression and knockdown 
studies on immortalized mouse endothelial cells (MECs).  Similar to results already seen in 
CIB1 null MLECs, MECs with CIB1 levels knocked down by short hairpin RNA show 
decreased migration on fibronectin (Zayed et al., 2007).  It still needs to be determined which 
integrin mediates these differences, so function-blocking antibodies to α5β1 or αVβ1 could be 
used. 
 For testing α2β1 activation, CIB1 null platelets can be isolated and analyzed by flow 
cytometry with FITC-labeled collagen, a ligand of α2β1.  If too few platelets are yielded from 
the mice, megakaryocytes can be harvested, cultured, and analyzed by flow cytometry.  Flow 
cytometry can also be performed on white cells isolated from CIB1 null mice with ligands 
for integrins found on white cells. 
 If appropriate ligands or antibodies are not available for use with mouse cells, or if 
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too few cells are obtained from mice, overexpression and knockdown experiments can be 
performed in cells such as NIH3T3 cells, which contain large amounts of CIB1, α5, and αV.  
Integrins have often been overexpressed in studies with talin.  Knockdown of talin inhibits 
activation of overexpressed αIIbβ3 and αVβ3 in CHO cells and α5β1 in NIH3T3 cells 
(Tadokoro et al., 2003).  Recombinant purified α4 tails are often used in studies with the α4-
binding protein paxillin.  It would be preferable to use endogenous integrin in studies with 
CIB1 so artifacts from overexpression can be avoided. 
 We will design point mutations to block the interaction of CIB1 with α integrin 
cytoplasmic tails and the activation state of integrins will be assessed.  An important 
consideration in designing point mutations of α integrins is whether a residue is part of the 
transmembrane or cytoplasmic interface between α and β subunits (see Fig. 1.4).  Studies of 
the interaction between αIIb and β3 in this region can help us predict which residues to mutate 
in other α integrins.  For αIIb, mutating the critical CIB1-binding residue W988 does not 
affect agonist-induced αIIbβ3 activation in 293T cells (Luo et al., 2005).  This mutation is 
expected to block CIB1 binding, so this data suggests that CIB1 inhibition of αIIbβ3 is not 
critical in this experimental setup.  The effect of CIB1 on the activation state of other α 
integrins could be more pronounced.  The effect of mutating the other αIIb transmembrane 
residue critical for binding CIB1, L983, has not been studied, although disulfide scanning of 
residues N-terminal to L983 indicates that this residue is part of the αIIbβ3 interface (Luo et 
al., 2004).  Of the two cytoplasmic residues critical for CIB1 binding, F992 is part of the 
αIIb/β3 interaction.  The F993 residue could be mutated to block CIB1 binding, although 
mutating this residue could disrupt the α-helix in this location.  Of the four residues of αIIb 
87
critical for CIB1 binding, W988 is most likely not to affect α/β interactions.  This residue is 
conserved as a Trp or Tyr in integrin α subunits.  Further study will determine whether 
mutating this residue blocks the effect of CIB1 on the activation of α integrins other than 
αIIb.  Once a mutant is determined to inhibit the interaction between CIB1 and α integrin, 
studies with this mutant can assess the importance of CIB1 in integrin function. 
 In resting αIIbβ3, the W988 residue of αIIb is predicted to be embedded within the 
plasma membrane on the border of the cytoplasmic face (Armulik et al., 1999).  The 
transmembrane border is expected to shift upon integrin activation, with residues through 
F992 of αIIb and I721 β3 predicted by NOE to be embedded in the membrane (Vinogradova 
et al., 2004).  Therefore, the transmembrane regions and their borders with the cytoplasm 
appear to be highly dynamic.  We propose that residues predicted to be embedded in the 
membrane shift out of the membrane upon binding to CIB1.  In order to study this, NOE 
studies will determine whether binding to CIB1 shifts the transmembrane borders of αIIb. 
 Residues on CIB1 necessary for α integrin binding could also be mutated to dissect 
the importance of CIB1 on integrin activation.  Many hydrophobic residues are predicted to 
be important for binding to αIIb (Barry et al., 2002;Yamniuk et al., 2006).  When assessing 
the effect of these mutants on integrin activation, the activation state of PAK1 should also be 
observed since CIB1 directly activates PAK1.  Effects of the mutants on integrin activation 
could occur indirectly through CIB1 activation of PAK1. 
 After determining the effect of CIB1 on integrin activation, many studies can be 
performed in addition to migration assays, as stated previously.  Overexpressed CIB1 induces 
focal adhesion formation in CHO cells on fibronectin (Naik, Naik, 2003a), and this can be 
further confirmed with knockdown studies and other cell types.  CIB1 is suggested to 
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participate in platelet spreading (Naik, Naik, 2003b) and FAK activation (Naik, Naik, 
2003a), and further study can elucidate further downstream effects of the interaction of CIB1 
with α integrins.  The effect of CIB1 on signaling pathways including FAK and the MAPK 
cascade should be studied, since these pathways are often involved in integrin signaling. 
 Live-cell microscopy can provide spatio-temporal information about the interaction 
between CIB1 and different α integrins.  In collaboration with Klaus Hahn, preliminary 
experiments have been performed using overexpressed fluorescently-tagged proteins in Cos-
7 cells (Yi Wu, unpublished data).  The α5 integrin was C-terminally tagged with cyan 
fluorescent protein (CFP) and CIB1 was C-terminally tagged with yellow fluorescent protein 
(YFP).  Initial experiments show a surprising lack of fluorescence resonance energy transfer 
(FRET), especially in membrane ruffles.  Both CIB1 and α5 were located in membrane 
ruffles although there was no FRET signal.  This could be due to the lack of agonist 
stimulation in these experiments, since CIB1 shows increased colocalization with αIIb upon 
agonist stimulation (Yuan et al., 2006b).  Future experiments can involve agonists or other 
cell types in order to determine the location and timing of CIB1 colocalization with integrins.  
Mouse embryonic fibroblast cells are more mobile and dynamic than Cos-7 cells, so these 
will be tested.  Having a tag at the C-terminus of CIB1 might affect ligand binding, so this 
should be considered.  As seen in sections 2.3.5 and 2.4.2, the C-terminal H10 helix of CIB1 
is most likely located within the hydrophobic binding pocket (Gentry et al., 2005;Yamniuk et 
al., 2006), and a tag might block access to the binding pocket or prevent the H10 helix from 
blocking nonspecific interactions.  A tag cannot be placed at the N-terminus of CIB1, 
because myristoylation, which can only occur at the G2 residue, might be important in its 
localization and function. These potential caveats must be taken into account in FRET 
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experiments. 
 Integrin-based therapeutics are mainstays in the treatment of cardiovascular disease 
and are gaining importance in treatment of other pathologies, such as autoimmune diseases.  
Existing therapeutics act as integrin antagonists by blocking adhesion to endogenous 
substrates.  A caveat to this approach is that antagonists act as partial agonists (Peter et al., 
2002) and might have undesirable downstream signalling effects, such as increased inside-
out signaling to additional integrins.  Antibody-based therapeutics such as abciximab and 
natalizumab can elicit immune responses.  Using natalizumab to block α4 function increases 
the risk of opportunistic infections like PML. 
 A different approach to designing therapeutics is to target the cytoplasmic tails of 
integrins.  Integrin tails are thought to separate upon activation, and the α/β interaction in 
resting cells acts as a clasp that maintains the integrin resting state.  Deletion of either of the 
cytoplasmic tails of αIIbβ3 results in integrin activation (O'Toole et al., 1994).  If tail 
separation can be prevented and the clasp integrity maintained, pathologies resulting from 
inappropriate integrin activation can be treated.  To better understand what drives tail 
separation, we must explore proteins that interact with cytoplasmic tails.  If we can determine 
the molecular mechanisms of integrin activation and inhibition by cytoplasmic proteins, it is 
possible that therapeutics could be modelled on these proteins.  A successful small molecule 
inhibitor has been discovered for the interaction between α4 and paxillin, which interacts C-
terminal to the predicted CIB1-interacting region of α4 (Ambroise et al., 2002).  Paxillin 
binding to α4 is required for efficient α4-mediated migration (Rose et al., 2003).  We must 
better understand the effect of CIB1 on α integrins before developing a small molecule 
therapeutic.  If CIB1 inhibits αIIbβ3 by blocking access to αIIb by talin or another cytoplasmic 
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protein, a therapeutic can target the CIB1-binding residues of αIIb and block interactions with 
activating proteins.  If CIB1 is somehow holding αIIbβ3 in a closed conformation, a CIB1 
mimetic might have the same function.  Conversely, if CIB1 is found to activate other 
integrins, CIB1 inhibition by a therapeutic could prevent disease states with overactive 
integrins.  It is likely that CIB1 displays differences in modulation of integrin activation with 
different integrins and cell types.  These differences could be useful in designing therapeutics 
with specificity for a specific integrin. 
 Aside from its possible role in therapeutics, CIB1 can help us to understand integrin 
activation.  Integrins are involved in many disease states, such as cardiovascular disease, 
cancer, and autoimmune diseases.  The role of CIB1 in transmembrane or cytoplasmic tail 
separation between α and β subunits is of special interest.  It is unknown how signals are 
transmitted from the cytoplasmic tails to the extracellular domains to affect ligand affinity.  It 
appears that outside-in signalling is at least partly transmitted by a shift in domain 
orientations between the β I and hybrid domains.  Whether similar conformational changes 
transmit signals in inside-out signalling is unknown.  Once we understand the effect of CIB1 
on α integrin cytoplasmic tails, we will learn much about the mechanism of integrin 
activation. 
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